<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1710246071
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cimuquit
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VARENICLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        194.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Lee Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Lee Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cimuquit contains the active substance varenicline.<br />Cimuquit is a medicine which is used in adults to help them stop smoking.<br />Cimuquit can help to relieve the craving and withdrawal symptoms associated with stopping<br />smoking.<br />Cimuquit can also reduce the enjoyment of cigarettes if you do smoke when on treatment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Cimuquit:<br />If you are allergic to varenicline or any of the other ingredients of this medicine (listed in section 6)<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Cimuquit.<br />There have been reports of depression, suicidal ideation and behaviour and suicide attempts in<br />patients taking Cimuquit. If you are taking Cimuquit and develop agitation, depressed mood, changes<br />in behaviour that are of concern to you or your family or if you develop suicidal thoughts or<br />behaviours you should stop taking Cimuquit and contact your doctor immediately for treatment<br />assessment.<br />The effects of stopping smoking<br />The effects of changes in your body resulting from stopping smoking, with or without treatment with<br />Cimuquit, may alter the way other medicines work. Therefore, in some cases an adjustment of the<br />dose may be necessary. See below under &lsquo;Other medicines and Cimuquit&rsquo; for further details.<br />For some people, stopping smoking with or without treatment has been associated with an increased<br />risk of experiencing changes in thinking or behaviour, feelings of depression and anxiety and can be<br />associated with a worsening of psychiatric disorder. If you have a history of psychiatric disorder you<br />should discuss this with your doctor.<br />Heart symptoms<br />New or worse heart or blood vessel (cardiovascular) problems have been reported primarily in<br />people who already have cardiovascular problems. Tell your doctor if you have any changes in<br />symptoms during treatment with Cimuquit. Get emergency medical help right away if you have<br />symptoms of a heart attack or stroke.<br />Seizures<br />Tell your doctor if you have experienced seizures or have epilepsy before your start Cimuquit<br />treatment. Some people have reported seizures while taking Cimuquit.<br />Hypersensitivity reactions<br />Stop taking Cimuquit and tell your doctor immediately if you experience any of the following signs<br />and symptoms that may indicate a serious allergic reaction: swelling of the face, lips, tongue, gums,<br />throat or body and/or difficulty breathing, wheezing.<br />Skin reactions<br />Potentially life-threatening skin rashes (Stevens-Johnson syndrome and Erythema Multiforme) have<br />been reported with the use of Cimuquit. If you develop a rash or if your skin starts to peel or blister<br />you should stop taking Cimuquit and seek emergency medical help.<br />Children and adolescents<br />Cimuquit is not recommended for use in paediatric patients as efficacy was not demonstrated<br />Other medicines and Cimuquit<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines<br />In some cases, as a result of stopping smoking, with or without Cimuquit, an adjustment of the dose<br />of other medicines may be necessary. Examples include theophylline (a medicine to treat breathing<br />problems), warfarin (a medicine to reduce blood clotting), and insulin (a medicine to treat diabetes).<br />If in doubt, you should consult your doctor or pharmacist.<br />If you have severe kidney disease you should avoid taking cimetidine (a medicine used for gastric<br />problems) at the same time as Cimuquit as this may cause increased blood levels of Cimuquit.<br />Use of Cimuquit with other therapies for smoking<br />cessation Consult your doctor before using Cimuquit in combination with other smoking cessation<br />therapies<br />Cimuquit with food and drink<br />There have been some reports of increased intoxicating effects of alcohol in patients taking<br />Cimuquit. However, it is not known if Cimuquit actually increases alcohol intoxication.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking this medicine.<br />It is preferable to avoid the use of Cimuquit while you are pregnant. Talk to your doctor if you are<br />intending to become pregnant.<br />Although it was not studied, Cimuquit may pass into breast milk. You should ask your doctor or<br />pharmacist for advice before taking Cimuquit.<br />Driving and using machines<br />Cimuquit may be linked with dizziness, sleepiness and transient loss of consciousness. You should<br />not drive, operate complex machinery or engage in any other potentially hazardous activities until<br />you know whether this medicine affects your ability to perform these activities.<br />Cimuquit contains sodium<br />This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially<br />&lsquo;sodium-free&rsquo;.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if<br />you are not sure.<br />You are more likely to stop smoking if you are motivated to stop. Your doctor and pharmacist can<br />provide advice, support and sources of further information to help ensure your attempt to stop<br />smoking is successful. Before starting your course of Cimuquit you should usually decide on a date<br />in the second week of treatment (between day 8 and day 14) when you will stop smoking. If you are<br />not willing or able to set a target quit date within 2 weeks, you may choose your own target quit date<br />within 5 weeks after starting treatment. You should write this date on the pack as a reminder.<br />Cimuquit comes as a white tablet (0.5 mg) and a light blue tablet (1 mg). You start with the white<br />tablet and then usually go to the light blue tablet. See the chart below for the usual dosing<br />instructions which you should follow from Day 1.</p><table><tbody><tr><td>Week 1</td><td>Dose</td></tr><tr><td>Day 1 - 3</td><td>From day 1 to day 3, you should take one white Cimuquit 0.5 mg film-coated tablet<br />once a day.</td></tr><tr><td>Day 4 - 7</td><td>From day 4 to day 7, you should take one white Cimuquit 0.5 mg film-coated tablet<br />twice daily, once in the morning and once in the evening, at about the same time<br />each day.</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>Week 2</td></tr><tr><td>Day 8 &ndash; 14</td><td>From day 8 to day 14, you should take one light blue Cimuquit 1 mg film-coated<br />tablet twice daily, once in the morning and once in the evening, at about the same<br />time each day.</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>Weeks 3 - 12</td></tr><tr><td>Day 15 -<br />end of<br />treatmen<br />t</td><td>From day 15 until the end of treatment, you should take one light blue Cimuquit<br />1 mg film-coated tablet twice daily, once in the morning and once in the evening,<br />at about the same time each day.</td></tr></tbody></table><p>After 12 weeks of treatment, if you have stopped smoking, your doctor may recommend an<br />additional 12 weeks of treatment with Cimuquit 1 mg film-coated tablets twice daily to help avoid<br />returning back to smoking.<br />If you are not able or willing to quit smoking straight away, you should reduce smoking during the<br />first 12 weeks of treatment and quit by the end of that treatment period. You should then continue to<br />take Cimuquit 1 mg film-coated tablets twice daily for a further 12 weeks resulting in a total of 24<br />weeks of treatment.<br />Should you experience adverse effects that you cannot tolerate your doctor may decide to reduce<br />your dose temporarily or permanently to 0.5 mg twice daily.<br />If you have problems with your kidneys, you should speak to your doctor before taking Cimuquit.<br />You may need a lower dose.<br />Cimuquit is for oral use.<br />The tablets should be swallowed whole with water and can be taken with or without food<br />If you take more Cimuquit than you should<br />If you accidentally take more Cimuquit than your doctor prescribed, you must seek medical<br />advice or go to the nearest hospital casualty department immediately. Take your box of tablets<br />with you.<br />If you forget to take Cimuquit<br />Do not take a double dose to make up for a forgotten tablet. It is important that you take<br />Cimuquit regularly at the same time each day. If you forget to take a dose, take it as soon as you<br />remember. If, it is within 3-4 hours before your next dose, do not take the tablet that you have<br />missed.<br />If you stop taking Cimuquit<br />It has been shown in clinical trials that taking all doses of your medicine at the appropriate times<br />and for the recommended duration of treatment described above will increase your chances of<br />stopping smoking. Therefore, unless your doctor instructs you to stop treatment, it is important to<br />keep taking Cimuquit, according to the instructions described in the table above.<br />In smoking cessation therapy, risk of returning to smoking may be elevated in the period<br />immediately following the end of treatment. You may temporarily experience increased irritability,<br />urge to smoke, depression and/or sleep disturbances when you stop taking Cimuquit. Your doctor<br />may decide to gradually lower your dose of Cimuquit at the end of treatment.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Giving up smoking with or without treatment can cause various symptoms. These could<br />include changes of mood (like feeling depressed, irritable, frustrated or anxious), sleeplessness,<br />difficulty concentrating, decreased heart rate and increased appetite or weight gain.<br />You should be aware of the possible emergence of serious neuropsychiatric symptoms, such as<br />agitation, depressed mood, or changes in behaviour during a quit attempt with or without Cimuquit<br />and you should contact a doctor or pharmacist if you experience such symptoms.<br />Serious side effects of either an uncommon or rare frequency have occurred in people attempting to<br />quit smoking with Cimuquit: seizure, stroke, heart attack, suicidal thoughts, loss of contact with<br />reality and unable to think or judge clearly (psychosis), changes in thinking or behaviour (such as<br />aggression and abnormal behaviour). There have also been reports of severe skin reactions including<br />Erythema Multiforme (a type of rash) and Stevens-Johnson Syndrome (a serious illness with<br />blistering of the skin, mouth, around the eyes or genitals) and serious allergic reactions including<br />angioedema (swelling of the face, mouth, or throat)<br />Very common: may affect more than 1 in 10 people<br />&bull; Inflammation of the nose and throat, abnormal dreams, difficulty sleeping, headache,<br />&bull; Nausea<br />Common: may affect up to 1 in 10 people<br />&bull; Chest infection, inflammation of the sinuses<br />&bull; Increased weight, decreased appetite, increased appetite<br />&bull; Sleepiness, dizziness, changes in the way things taste<br />&bull; Shortness of breath, cough<br />&bull; Heartburn, vomiting, constipation, diarrhoea, feeling bloated, abdominal pain, toothache,<br />indigestion, flatulence, dry mouth<br />&bull; Skin rash, itching<br />&bull; Joint ache, muscle ache, back pain<br />&bull; Chest pain, tiredness<br />Uncommon: may affect up to 1 in 100 people<br />&bull; Fungal infection, viral infection<br />&bull; Feeling of panic, difficulty thinking, restlessness, mood swings, depression, anxiety,<br />hallucinations, changes in sex drive<br />&bull; Seizure, tremor, feeling sluggish, less sensitive to touch<br />&bull; Conjunctivitis, eye pain<br />&bull; Ringing in the ears<br />&bull; Angina, rapid heart rate, palpitations, increased heart rate<br />&bull; Increased blood pressure, hot flush<br />&bull; Inflammation of nose, sinuses and throat, congestion of nose, throat and chest, hoarseness, hay<br />fever, throat irritation, congested sinuses, excess mucous from nose causing cough, runny nose<br />&bull; Red blood in stools, irritated stomach, change of bowel habit, belching, mouth ulcers, pain in<br />the gums<br />&bull; Reddening of the skin, acne, increased sweating, night sweats<br />&bull; Muscle spasms, chest wall pain<br />&bull; Abnormally frequent urination, urination at night<br />&bull; Increased menstrual flow<br />&bull; Chest discomfort, flu like illness, fever, feeling weak or unwell<br />&bull; High blood sugar<br />&bull; Heart attack<br />&bull; Suicidal thoughts<br />&bull; Changes in thinking or behaviour (such as aggression)<br />Rare: may affect up to 1 in 1,000 people<br />&bull; Excessive thirst<br />&bull; Feeling unwell or unhappy, slow thinking<br />&bull; Stroke<br />&bull; Increased muscle tension, difficulty with speech, difficulty with coordination, reduced sense of<br />taste, altered sleep pattern<br />&bull; Disturbed vision, eyeball discolouration, dilated pupils, sensitivity to light, shortsightedness,<br />watery eyes<br />&bull; Irregular heart beat or heart rhythm disturbances<br />&bull; Throat pain, snoring<br />&bull; Blood in vomit, abnormal stools, coated tongue<br />&bull; Stiff joints, rib pain<br />&bull; Glucose in urine, increased urine volume and frequency<br />&bull; Vaginal discharge, changes in sexual ability<br />&bull; Feeling cold, cyst<br />&bull; Diabetes<br />&bull; Sleep walking<br />&bull; Loss of contact with reality and unable to think or judge clearly (psychosis)<br />&bull; Abnormal behaviour<br />&bull; Severe skin reactions including Erythema Multiforme (a type of rash) and Stevens- Johnson<br />Syndrome (a serious illness with blistering of the skin, mouth, around the eyes or genitals)<br />&bull; Serious allergic reactions including angioedema (swelling of the face, mouth, or throat)<br />Not known<br />&bull; Transient loss of consciousness<br />Reporting of side effects<br />If any of the side effects get serious, or if you notice any side effects not listed in this<br />leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />&bull; SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/</p><p>&bull; United Arab Emirates</p><p>Pharmacovigilance &amp; Medical Device sectionP.O.Box: 1853<br />Tel: 80011111Email :pv@mohap.gov.ae<br />Drug Department Ministry of Health &amp; Prevention, Dubai, UAE</p><p>&bull; Other GCC States:<br />Please contact the relevant competent authority.<br />Council of Arab Health Ministers<br />This is a Medicament<br />&bull; Medicament is a product which affects your health and its consumption contrary to instructions is<br />dangerous for you.<br />&bull; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist<br />who sold the medicament.<br />&bull; The doctor and the pharmacist are the experts in medicines, their benefits and risks.<br />&bull; Do not by yourself interrupt the period of treatment prescribed for you.<br />&bull; Do not repeat the same prescription without consulting your doctor.<br />&bull; Keep all medicaments out of reach of children.<br />Council of Arab Health Ministers<br />Union of Arab Pharmacists<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&deg;C.<br />&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the box/blisters after EXP.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist<br />how to throw away medicines you no longer use. These measures will help protect the<br />environment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Cimuquit contains:<br />The active substance is varenicline.<br />- Each 0.5 mg film-coated tablet contains 0.5 mg of varenicline (as tartrate).<br />- Each 1 mg film-coated tablet contains 1 mg of varenicline (as tartrate).<br />The other ingredients are:<br />Tablet Core - Cimuquit 0.5 mg and 1 mg film-coated tablets<br />- Microcrystalline Cellulose<br />- Di calcium Phosphate Anhydrous<br />- Croscarmellose Sodium (see section 2 &ldquo;Cimuquit contains sodium&rdquo;<br />- Colloidal Silica Anhydrous<br />- Magnesium Stearate<br />Tablet film coating - Cimuquit 0.5 mg film-coated tablets<br />- Opadry White<br />- Purified water<br />Tablet film coating - Cimuquit 1 mg film-coated tablets<br />- Opadry Blue<br />- Hypromellose (HPMC-E3)<br />- Purified water<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cimuquit comes in two tablet strengths:
Cimuquit 0.5 mg film-coated tablets are White capsular shaped biconvex tablet plain on both sides.
Cimuquit 1 mg film-coated tablets are Light blue color capsular biconvex tablet with plain on both sides
Cimuquit Tablets are provided in Blister packs. Blisters are packed in a carton along with a patient
information leaflet
Cimuquit film-coated tablets are provided in pack sizes of 25 tablets and 56 tablets
Cimuquit is available in the following pack presentations:
- A treatment initiation pack containing 2 blisters; 1 clear blister of 11 x Cimuquit 0.5 mg film coated
tablets and 1 clear blister of 14 x Cimuquit 1 mg film-coated tablets in a carton box packaging.
- A follow-on (maintenance) pack containing 4 clear blisters of 14 x Cimuquit 0.5 mg film-coated
tablets in a carton box packaging.
- A follow-on (maintenance) pack containing 4 clear blisters of 14 x Cimuquit 1mg film coated
tablets in in a carton box packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong>:<br />Lee Pharma Limited,<br />Plot No. V, Phase-II, VSEZ,<br />Duvvada, Sabbavaram (M),<br />Visakhapatnam District - 530049,<br />Andhra Pradesh, India</p><p>S<strong>econdary packaging and Marketing Authorization Holder:</strong><br />Batterjee Pharmaceutical Factory (BATTERJEE PHARMA)<br />Plot E2, Phase 4, Industrial City, Jeddah, Saudi Arabia<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي سيموكويت على المادة الفعالة فارينيكلين.<br />سيموكويت هو دواء يستخدم للبالغين لمساعدتهم على الإقلاع عن التدخين.<br />يمكن أن يساعد السيموكويت في تخفيف أعراض الرغبة الشديدة والانسحاب المرتبطة بالتوقف عن التدخين.<br />يمكن لـسيموكويت أي ًضا أن يقلل من الاستمتاع بالسجائر إذا كنت تدخن أثناء العلاج<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول سيموكويت:<br />&bull; إذا كنت مصابًا بالحساسية من الفارينيكلين أو أي مكون آخر من مكونات هذا الدواء (ال ُمدرجة في القسم )6<br />التحذيرات والاحتياطات<br />تحدث مع طبيبك او الصيدلي الخاص بك قبل تناول سيموكويت<br />هناك تقارير عن الإصابة بالاكتئاب والتعرض لأفكار وسلوك انتحاري ومحاولات انتحار في المرضى الذين يتناولون سيموكويت. إذا<br />كنت تتناول سيموكويت وأ ِصبت بهياج أو مزاج مكتئب أو تغيرات في السلوك قد تثير قلقك أو قلق عائلتك أو إذا خطرت لك أفكار أو<br />سلوكيات انتحارية، ينبغي أن توقف تناول سيموكويت وتتصل بطبيبك في الحال لتقييم العلاج.<br />تأثيرات الإقلاع عن التدخين<br />قد تتسبب تأثيرات التغيرات التي تحدث في الجسم نتيجة الإقلاع عن التدخين، مع أو دون العلاج بسيموكويت، في تغيير الطريقة التي<br />تعمل بها الأدوية الأخرى. لذا قد يكون تعديل الجرعة ضروريًا في بعض الحالات. انظر أدناه تحت عنوان &quot;الأدوية الأخرى<br />وسيموكويت&quot; للمزيد من التفاصيل.<br />بالنسبة لبعض الأشخاص، يصاحب الإقلاع عن التدخين مع أو دون العلاج خطر متزايد لحدوث تغيرات في التفكير أو السلوك أو الشعور<br />بالاكتئاب والقلق كما وقد يصاحبه تفاقم الاضطراب النفسي. إذا كان لديك تاري ًخا مرضيا للمعاناة من أي اضطراب نفسي ينبغي أن تناقش<br />هذا الأمر مع طبيبك .<br />الأعراض القلبية<br />تم الإبلاغ عن حدوث مشكلات قلبية أو تتعلق بالأوعية الدموية (قلبية وعائية) حديثة أو تفاقم حالتها بشكل رئيسي في الأشخاص<br />المصابين بالفعل بأمراض قلبية وعائية. أخبر طبيبك إذا أصبت بأي تغير في الأعراض أثناء علاجك بسيموكويت. احصل على مساعدة<br />طبية طارئة في الحال إذا أصابتك أعراض أزمة قلبية أو سكتة دماغية.<br />النوبات<br />أخبر طبيبك إذا تعرضت لنوبات صرع أو كنت مصابًا بالصرع قبل أن تبدأ في العلاج بسيموكويت. أبلغ بعض الأشخاص عن الإصابة<br />بنوبات أثناء تناول سيموكويت.<br />تفاعلات فرط حساسية<br />توقف عن تناول سيموكويت وأخبر طبيبك على الفور إذا أصبت بأي من العلامات والأعراض التالية التي قد تشير إلى رد فعل تحسسي<br />خطير: تورم الوجه أو الشفتين أو اللسان أو اللثة أو الحلق أو الجسم و/أو صعوبة في التنفس، أزيز.<br />تفاعلات جلدية<br />تم الإبلاغ عن طفح جلدي يحتمل أن يكون مهددًا للحياة (متلازمة ستيفنز جونسون والاحمرار عديد الأشكال) عند استخدام سيموكويت.<br />إذا أصبت بطفح جلدي أو إذا بدأ جلدك في التقشر أو التبثر، ينبغي أن تتوقف عن تناول سيموكويت واطلب المساعدة الطبية الطارئة.<br />الأطفال والمراهقين<br />لا ينصح باستخدام السيموكويت في مرضى الأطفال حيث لم يتم إثبات فعاليته<br />الأدوية الأخرى وسيموكويت<br />أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخ ًرا أو من الممكن أن تتناول أي أدوية أخرى.<br />في بعض الحالات كنتيجة للإقلاع عن التدخين، مع أو دون العلاج بسيموكويت، قد يكون تعديل الجرعة للأدوية الأخرى ضروريًا.<br />تتضمن الأمثلة ثيوفيلين (دواء لعلاج مشاكل التنفس،) ووارفارين (دواء لتقليل تخثر الدم)، والإنسولين (دواء لعلاج مرض السكري). إذا<br />كنت غير واثق مما عليك فعله، ينبغي أن تستشير طبيبك أو الصيدلي.<br />إذا كنت تعاني من مرض كلوي حاد ينبغي أن تتجنب تناول سيميتيدين (دواء يستخدم لعلاج مشاكل المعدة) بالتزامن مع سيموكويت حيث<br />قد يسبب ذلك ارتفاع مستويات سيموكويت في الدم.<br />استخدام سيموكويت مع علاجات الإقلاع عن التدخين الأخرى:<br />استشر طبيبك قبل تناول سيموكويت بالتزامن مع علاجات أخرى للإقلاع عن التدخين.<br />سيموكويت مع الطعام والشراب<br />كانت هناك بعض البلاغات حول زيادة آثار الثمالة من الكحول في المرضى الذين يتناولون سيموكويت.<br />مع ذلك، ليس معروفًا إذا كان سيموكويت يزيد بالفعل من آثار الثمالة من الكحول أم لا<br />الحمل والرضاعة<br />إذا كن ِت حام ًلا أو ترضعين رضاعة طبيعية، أو تعتقدين أن ِك ربما تكونين حام ًلا أو تخططين للحمل، فاستشيري طبيب ِك أو الصيدلي قبل<br />تناول هذا الدواء.<br />يُفضل تجنب استخدام سيموكويت أثناء الحمل .<br />قومي باستشارة طبيبك إذا كنت تخططين للحمل.<br />على الرغم من عدم دراسة الأمر إلا أن سيموكويت قد يمر إلى لبن الأم. يجب علي ِك استشارة طبيبك أو الصيدلي قبل تناول سيموكويت.<br />القيادة واستخدام الآلات<br />قد يرتبط استخدام سيموكويت بالشعور بالدوار والنعاس وفقدان الوعي العابر. ينبغي عليك تجنب القيادة أو تشغيل الماكينات المعقدة أو<br />المشاركة في أي أنشطة أخرى ذات خطورة محتملة حتى تتأكد مما إذا كان هذا الدواء يؤثر على قدرتك على القيام بهذه الأنشطة.<br />يحتوي سيموكويت على الصوديوم<br />يحتوي هذا الدواء على أقل من 1مليمول صوديوم ( 23مجم) لكل قرص، وهذا يعني بشكل أساسي &quot;خا ٍل من الصوديوم&quot;.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دو ًما على تناول هذا الدواء تما ًما كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأك ًدا مما يجب عليك فعله.<br />يكون الاحتمال أكبر في أن تقلع عن التدخين إذا كان لديك الحافز لتتوقف. يمكن لطبيبك أو الصيدلي أن يقدما لك النصيحة والدعم<br />ومصادر المزيد من المعلومات لمساعدتك في التأكد من نجاح محاولتك للإقلاع عن التدخين .<br />قبل أن تبدأ في علاجك بسيموكويت ينبغي عادة أن تحدد يو ًما في الأسبوع الثاني من العلاج (ما بين اليوم 8واليوم )14حيث ستتوقف<br />فيه عن التدخين. إذا لم تكن راغبًا أو قاد ًرا على وضع يوم مستهدف لتاريخ الإقلاع في خلال أسبوعين، يمكنك اختيار تاريخ الإقلاع<br />المستهدف الخاص بك في خلال 5أسابيع بعد بدء العلاج. ينبغي أن تقوم بكتابة هذا التاريخ على العبوة كرسالة تذكير.<br />يأتي سيموكويت في صورة أقراص بيضاء ( 0.5ملجم) وأقراص بلون أزرق فاتح ( 1ملجم). عادة ما تبدا العلاج بالأقراص البيضاء ثم<br />تنتقل إلى الأقراص بالون الأزرق الفاتح. انظر إلى الجدول أدناه لمعرفة تعليمات الجرعات المعتادة والتي ينبغي أن تتبعها من اليوم الاول</p><table><tbody><tr><td>الأسبوع 1</td><td>الجرعة</td></tr><tr><td>من اليوم 1إلى اليوم ،3ينبغي أن تتناول قرص واحد أبيض من أقراص سيموكويت 0.5ملجم المغلفة بطبقة<br />رقيقة مرة واحدة يوميًا.</td><td>الأيام 3 -1</td></tr><tr><td>من اليوم 4إلى اليوم ،7ينبغي أن تتناول قرص واحد أبيض من أقراص سيموكويت 0.5ملجم المغلفة بطبقة<br />رقيقة مرتين يوميًا، قرص في الصباح وقرص في المساء، في نفس الوقت تقريبًا كل يوم.</td><td>الأيام 7 -4</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>الأسبوع 2</td><td>الجرعة</td></tr><tr><td>من اليوم 8إلى اليوم ،14ينبغي أن تتناول قرص واحد أزرق فاتح من أقراص سيموكويت 1ملجم المغلفة<br />بطبقة رقيقة مرتين يوميًا، قرص في الصباح وقرص في المساء، في نفس الوقت تقريبًا كل يوم.</td><td>الأيام 14-8</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>الأسابيع 12-3</td><td>الجرعة</td></tr><tr><td>من اليوم 15إلى نهاية العلاج، ينبغي أن تتناول قرص واحد أزرق فاتح من أقراص سيموكويت 1ملجم المغلفة<br />بطبقة رقيقة مرتين يوميًا، قرص في الصباح وقرص في المساء، في نفس الوقت تقريبًا كل يوم.</td><td>الأيام -15نهاية<br />العلاج</td></tr></tbody></table><p>بعد 12أسبو ًعا من العلاج، إذا كنت قد اقلعت عن التدخين، قد يوصي طبيبك بـ 12أسبو ًعا إضافيًا من العلاج بأقراص سيموكويت<br />1ملجم المغلفة مرتين يوميًا. للمساعدة على تجنب العودة للتدخين مرة أخرى.<br />إذا لم تكن قاد ًرا أو راغبًا في الإقلاع عن التدخين على الفور، ينبغي عليك خفض معدل تدخينك خلال الأسابيع ال 12الأولى من العلاج<br />والإقلاع عن التدخين بنهاية فترة العلاج. ثم ينبغي عليك بعدئذٍ الاستمرار في تناول أقراص سيموكويت 1ملجم المغلفة بطبقة رقيقة مرتين<br />يوميًا لمدة 12أسبو ًعا إضافية لتكون بذلك قد خضعت لفترة علاج تبلغ 24أسبو ًعا .<br />إذا تعرضت لتأثيرات ضارة لا يمكنك تحملها فقد يقرر طبيبك أن يقلل الجرعة الخاصة بك بشكل مؤقت أو دائم إلى 0.5ملجم مرتين<br />يوميًا.<br />إذا كنت تعاني من مشاكل في الكلي، ينبغي أن تستشير طبيبك قبل تناول سيموكويت. فقد تحتاج لتناول جرعة أقل.<br />سيموكويت مخصص للتناول عن طريق الفم.<br />ينبغي بلع الأقراص بالكامل مع الماء ويمكن تناولها مع الطعام أو بدونه.<br />إذا تناولت جرعة من سيموكويت أكثر مما ينبغي<br />إذا تناولت عن طريق الخطأ سيموكويت أكثر مما وصفه طبيبك، فيجب عليك طلب المشورة الطبية أو الذهاب إلى أقرب قسم طوارئ في<br />المستشفى على الفور. خذ علبة الأقراص معك<br />إذا نسيت تناول سيموكويت<br />لا تأخذ جرعة مضاعفة لتعويض قرص منسي. من المهم أن تتناول السيموكويت بانتظام في نفس الوقت كل يوم. إذا نسيت تناول جرعة،<br />فتناولها حالما تتذكرها. إذا كان ذلك في غضون 4-3ساعات قبل الجرعة التالية، فلا تتناول القرص الذي فاتك.<br />إذا توقفت عن تناول سيموكويت<br />لقد ثبت في التجارب السريرية أن تناول جميع جرعات دوائك في الأوقات المناسبة وللمدة الموصي بها للعلاج الموصوف أعلاه سيزيد من<br />فرصك في التوقف عن التدخين. لذلك، ما لم يطلب منك طبيبك التوقف عن العلاج، فمن المهم الاستمرار في تناول السيموكويت، وفقًا<br />للتعليمات الموضحة في الجدول أعلاه.<br />في علاج الإقلاع عن التدخين، قد يرتفع خطر العودة إلى التدخين في الفترة التي تلي انتهاء العلاج مباشرة. قد تعاني مؤقتًا من زيادة التهيج،<br />والحاجة إلى التدخين، والاكتئاب و/أو اضطرابات النوم عند التوقف عن تناول السيموكويت. قد يقرر طبيبك خفض جرعتك تدريجياً من<br />السيموكويت في نهاية العلاج.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثا ًرا جانبية، رغم أنها لا تصيب الجميع.<br />قد يتسبب التوقف عن التدخين مع أو دون علاج في حدوث أعراض عديدة. قد تتضمن هذه الأعراض التغيرات المزاجية (مثل الشعور<br />بالاكتئاب أو الانزعاج أو الإحباط أو القلق) والأرق وصعوبة التركيز وانخفاض معدل ضربات القلب وانفتاح الشهية أو زيادة الوزن.<br />ينبغي أن تكون على دراية باحتمال ظهور أعراض نفسية عصبية خطيرة، مثل الهياج أو مزاج مكتئب أو تغيرات في السلوك أثناء<br />محاولة الإقلاع عن التدخين مع سيموكويت أو دونه وينبغي عليك التواصل مع الطبيب أو الصيدلي إذا أصبت بهذه الأعراض.<br />حدثت آثار جانبية خطيرة بمعدل تكرار غير شائع أو نادر في المرضى الذين حاولوا الإقلاع عن التدخين مع سيموكويت: نوبات وسكتة<br />دماغية وأزمة قلبية وأفكار انتحارية وفقدان الاتصال بالواقع وعدم القدرة على التفكير أو الحكم بشكل واضح (الذهان) وتغيرات في<br />التفكير أو السلوك (مثل العدوانية والسلوك غير الطبيعي). كانت هناك بلاغات أي ًضا بتفاعلات جلدية شديدة بما في ذلك الاحمرار عديد<br />الأشكال (نوع من الطفح الجلدي) ومتلازمة ستيفنز جونسون (مرض خطير يتضمن تبثر الجلد أو الفم أو المنطقة المحيطة بالعينين أو<br />الأعضاء التناسلية) وتفاعلات حساسية خطيرة بما في ذلك التورم الوعائي (تورم الوجه أو الفم أو الحلق).<br />شائعة جدًا: قد تؤثر على أكثر من فرد واحد بين كل 10أفراد</p><table><tbody><tr><td>&bull;<br />&bull;</td><td>التهاب الأنف والحلق، الأحلام غير الطبيعية، الصعوبة في النوم، صداع<br />الغثيان</td></tr></tbody></table><p>شائعة: قد تؤثر على ما يصل إلى فرد واحد بين كل 10أفراد</p><table><tbody><tr><td>&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;</td><td>التهاب في الصدر، التهاب الجيوب الأنفية<br />زيادة الوزن، ضعف في الشهية، انفتاح في الشهية<br />النعاس، الدوار، تغيرات في مذاق الأشياء<br />ضيق التنفس، سعال<br />حرقة فم المعدة، القيء، الإمساك، الإسهال، الشعور بالانتفاخ، ألم في البطن، ألم في الأسنان، عسر الهضم، انتفاخ البطن ، جفاف</td><td>الفم<br />طفح جلدي، حكة<br />ألم في الصدر، إرهاق</td><td>ألم في المفاصل، ألم في العضلات، ألم في الظهر</td></tr></tbody></table><p><br />غير شائعة: قد تؤثر على ما يصل إلى فرد واحد بين كل 100فرد</p><table style="width:642.891px"><tbody><tr><td style="width:1px">&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;</td><td style="width:647.109px">عدوى بالفطريات<br />العدوى الفيروسية<br />الشعور بالفزع، الصعوبة في التفكير، التململ ,التغيرات المزاجية، الاكتئاب، القلق، الهلاوس، تغيرات في الدافع الجنسي<br />التشنجات، الرعاش، الشعور بالثقل، انخفاض الاحساس بحاسة اللمس<br />التهاب الملتحمة، ألم في العين<br />طنين في الأذن<br />الذبحة الصدرية، سرعة ضربات القلب، خفقان في القلب، زيادة معدل ضربات القلب<br />ارتفاع ضغط الدم، احمرار وسخونة في الوجه<br />التهاب الأنف، الجيوب الأنفية والحلق، احتقان الأنف، الحلق والصدر، بحة في الصوت، حمى القش، تهيج الحلق، احتقان الجيوب<br />الأنفية، زيادة المخاط من الأنف مما يسبب السعال، سيلان الانف.<br />وجود دم أحمر في البراز، تهيج المعدة، تغير في عادة الأمعاء، التجشؤ، قرح الفم، ألم اللثة<br />احمرار الجلد، البثور، زيادة التعرق، التعرق الليلي<br />تشنج في العضلات، ألم بجدار الصدر<br />تكرار التبول بشكل غير طبيعي، التبول أثناء الليل<br />زيادة تدفق الحيض<br />انزعاج في الصدر، أعراض شبيهة بالإنفلونزا، الحمى، الشعور بالضعف أو التوعك<br />ارتفاع سكر الدم<br />الأزمة القلبية<br />الأفكار الانتحارية<br />تغيرات في التفكير أو السلوك (مثل العدوانية)</td></tr><tr><td style="width:1px">&nbsp;</td></tr></tbody></table><p>نادرة: قد تؤثر على ما يصل إلى فرد واحد بين كل 1000فرد</p><table><tbody><tr><td>&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;<br />&bull;</td><td>الشعور بالعطش الشديد<br />الشعور بالإعياء وعدم السعادة، التفكير البطيء<br />السكتة الدماغية<br />زيادة توتر العضلات، صعوبة في الكلام، صعوبة في التنسيق، انخفاض في حاسة التذوق، تغير نمط النوم<br />تشوش الرؤية تغير لون مقلة العين، اتساع حدقة العين، الحساسية تجاه الضوء، قصر النظر، عيون دامعة<br />عدم انتظام ضربات القلب أو اضطراب ضربات القلب<br />ألم في الحلق، شخير<br />دم في القيء، براز غير طبيعي، لسان مبيض<br />تصلب المفاصل، ألم في أضلع الصدر<br />وجود جلوكوز في البول، زيادة كمية وتكرار البول<br />إفرازات مهبلية، تغيرات في الرغبة أو القدرة الجنسية<br />الشعور بالبرد، الكيسة<br />داء السكري<br />المشي أثناء النوم<br />فقدان الاتصال بالواقع وعدم القدرة على التفكير أو الحكم بوضوح (الذهان)<br />السلوك غير الطبيعي<br />تفاعلات جلدية خطيرة بما في ذلك ُحما َمي عديدة الأشكال (نوع من أنواع الطفح الجلدي) ومتلازمة ستيفنز-جونسون (مرض<br />خطير يتميز بوجود تقرحات في الجلد أو الفم أو حول العينين أو المناطق التناسلية)<br />تفاعلات حساسية خطيرة بما في ذلك الوذمة الوعائية (تورم الوجه، الفم أو الحلق).</td></tr><tr><td>&bull;</td></tr></tbody></table><p>غير معروف<br />&bull; فقدان عابر للوعي<br />الإبلاغ عن الأعراض الجانبية:<br />إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلاً أبلغ الطبيب أو الصيدلي</p><p>&nbsp;</p><p>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجي التواصل عبر العناوين التالية:</p><p>&bull; المملكة العربية السعودية:</p><p>-المركز الوطني للتيقظ الدوائي:</p><p>رقم الاتصال الموحد : 19999<br />npc.drug@sfda.gov.sa. :البريد الإلكتروني<br />https://ade.sfda.gov.sa :الموقع الإلكتروني</p><p>&bull; الإمارات العربية المتحدة:</p><p>قسم التيقظ الدوائي والأجهزة الطبية<br />صندوق بريد: 1853</p><p>80011111 :هاتف<br />بريد إلكتروني: pv@mohap.gov.ae<br />إدارة الدواء وزارة الصحة ووقاية المجتمع<br />دبي ، الإمارات العربية المتحدة</p><p>&bull; دول الخليج العربي الأخرى:</p><p>الرجاء الاتصال بالجهات الوطنية في كل دولة<br /><br /><br /><br /><br />مجلس وزراء الصحة العرب:</p><table><tbody><tr><td>إن هذا الدواء<br />- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافا للتعليمات يعرضك للخطر.<br />- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.<br />- الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.<br />- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.<br />- لا تكرر صرف الدواء بدون استشارة الطبيب المختص.<br />- لا تترك الأدوية في متناول الأطفال.</td></tr></tbody></table><p>مجلس وزراء الصحة العرب<br />واتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table><tbody><tr><td>يحفظ في درجة حرارة لا تزيد عن 30درجة مئوية.<br />يحفظ بعيدًا عن رؤية ومتناول الأطفال.<br />لا تستخدم هذا العقار بعد تاريخ انتهاء صلاحيته المدون على العلبة/الشرائط بعد كلمة</td><td>&bull;<br />&bull;<br />&bull;</td></tr><tr><td>(.)EXP<br />لا تتخلص من الأدوية بإلقائها في مياه الصرف الصحي أو النفايات المنزلية، اسألي الصيدلي الخاص بك عن إجراءات التخلص</td></tr><tr><td>من الأدوية التي لم تعد تستعملها، حيث تساعد هذه الإجراءات في حماية البيئة</td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مكونات عقار سيموكويت<br />المادة الفعالة هي الفارينيكلين.<br />- يحتوي كل قرص مغلف 0.5مجم على 0.5مجم فارينيكلين (طرطرات.)<br />- يحتوي كل قرص مغلف 1مجم على 1مجم فارينيكلين (على شكل طرطرات.)<br />المكونات الأخرى هي<br />الطبقة الداخلية لأقراص سيموكويت 0.5مجم و 1مجم<br />- السليلوز دقيق التبلور<br />- ثاني فوسفات الكالسيوم اللامائي<br />- كروسكارميلوز الصوديوم (انظر القسم &quot; 2سيموكويت يحتوي على الصوديوم&quot;<br />- السيليكا الغروية اللامائية<br />- ستيرات المغنيسيوم<br />الطبقة الخارجية لأقراص سيموكويت 0.5مجم<br />- أوبادري أبيض<br />- ماء نقي<br />الطبقة الخارجية لأقراص سيموكويت 1مجم<br />- هيبروميلوز<br />- أوبادري أزرق<br />- ماء نقي<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر أقراص سيموكويت في تركيزين<br />أقراص سيموكويت 0.5مجم عبارة عن أقراص مغلفة ذات شكل كبسولي بيضاء محدبة ومسطحة من كلا الجانبين<br />أقراص سيموكويت 1مجم عبارة عن أقراص مغلفة ذات شكل كبسولي محدبة بلون أزرق فاتح ومسطحة من كلا الجانبين<br />تتوفر أقراص سيموكويت في شرائط. يتم تعبئة الشرائط في علبة كرتون مع نشرة معلومات للمريض<br />تتوافر أقراص سيموكويت المغلفة في عبوات بأحجام 25قرصاً و 56قرصاً<br />سيموكويت متاح في أشكال العبوات التالية:<br />- عبوة بدء علاج تحتوي على شريطين، شريط شفاف واحد به 0.5 &times;11ملجم أقراص سيموكويت وشريط 1 &times; 14ملجم أقراص<br />سيموكويت في عبوة كرتونية.<br />- عبوة متابعة (مداومة) تحتوي على 4شرائط شفافة بهما 0.5 x 14ملجم أقراص سيموكويت في عبوة كرتونية.<br />- عبوة متابعة (مداومة) تحتوي على 4شرائط شفافة بهما 1 x14ملجم أقراص سيموكويت في عبوة كرتونية<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الصانع</strong>:<br />لي فارما المحدودة ،<br />قطعة رقم ، 5المرحلة الثانية ، المنطقة الاقتصادية الخاصة ،<br />دوفادا ، سابافارام ،<br />منطقة فيساخاباتنام - ، 530049<br />ولاية اندرا براديش ، الهند</p><p><strong>التغليف الثانوي و مالك رخصة التسويق</strong><br />مصنع البترجي للأدوية (بترجي فارما)<br />المملكة العربية السعودية، جدة، المنطقة الصناعية، المرحلة الرابعة، قطعة E<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر  2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cimuquit 0.5 mg film-coated tablets
Cimuquit 1 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 0.5 mg film-coated tablet contains 0.5 mg of varenicline (as tartrate).
Each 1 mg film-coated tablet contains 1 mg of varenicline (as tartrate).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets
Cimuquit 0.5 mg film-coated tablets are white capsular shaped biconvex tablet plain on both sides
Cimuquit 1 mg film-coated tablets are Light blue colour capsular biconvex tablet with plain on both sides
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cimuquit is indicated for smoking cessation in adults.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The recommended dose is 1 mg varenicline twice daily following a 1-week titration as follows:</p><table><tbody><tr><td>Days 1 &ndash; 3:</td><td>0.5 mg once daily</td></tr><tr><td>Days 4 &ndash; 7:</td><td>0.5 mg twice daily</td></tr><tr><td>Day 8 &ndash; End of treatment:</td><td>1 mg twice daily</td></tr></tbody></table><p>The patient should set a date to stop smoking. CIMUQUIT dosing should usually start at 1-2 weeks<br />before this date (see section 5.1). Patients should be treated with CIMUQUIT for 12 weeks.<br />For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12<br />weeks treatment with CIMUQUIT at 1 mg twice daily may be considered for the maintenance of<br />abstinence (see section 5.1).<br />A gradual approach to quitting smoking with CIMUQUIT should be considered for patients who are<br />not able or willing to quit abruptly. Patients should reduce smoking during the first 12 weeks of<br />treatment and quit by the end of that treatment period. Patients should then continue taking<br />CIMUQUIT for an additional 12 weeks for a total of 24 weeks of treatment (see section 5.1).<br />Patients who are motivated to quit and who did not succeed in stopping smoking during prior CIMUQUIT<br />therapy, or who relapsed after treatment, may benefit from another quit attempt with CIMUQUIT (see<br />section 5.1).<br />Patients who cannot tolerate adverse reactions of CIMUQUIT may have the dose lowered temporarily or<br />permanently to 0.5 mg twice daily.<br />In smoking cessation therapy, risk for relapse to smoking is elevated in the period immediately following<br />the end of treatment. In patients with a high risk of relapse, dose tapering may be considered (see section<br />4.4).<br />Elderly<br />No dosage adjustment is necessary for elderly patients (see section 5.2). Because elderly patients are<br />more likely to have decreased renal function, prescribers should consider the renal status of an elderly<br />patient.<br />Renal impairment<br />No dosage adjustment is necessary for patients with mild (estimated creatinine clearance &gt; 50 ml/min<br />and &le; 80 ml/min) to moderate (estimated creatinine clearance &ge; 30 ml/min and &le; 50 ml/min) renal<br />impairment.<br />For patients with moderate renal impairment who experience adverse reactions that are not tolerable,<br />dosing may be reduced to 1 mg once daily.<br />For patients with severe renal impairment (estimated creatinine clearance &lt; 30 ml/min), the<br />recommended dose of CIMUQUIT is 1 mg once daily. Dosing should begin at 0.5 mg once daily for<br />the first 3 days then increased to 1 mg once daily. Based on insufficient clinical experience with<br />CIMUQUIT in patients with end-stage renal disease, treatment is not recommended in this patient<br />population (see section 5.2).<br />Hepatic impairment<br />No dosage adjustment is necessary for patients with hepatic impairment (see section 5.2).<br />Paediatric population<br />CIMUQUIT is not recommended for use in paediatric patients because its efficacy in this population<br />was not demonstrated (see sections 5.1 and 5.2).</p><p>Method of administration<br />CIMUQUIT is for oral use and the tablets should be swallowed whole with<br />water. CIMUQUIT can be taken with or without food</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of smoking cessation<br />Physiological changes resulting from smoking cessation, with or without treatment with CIMUQUIT, may<br />alter the pharmacokinetics or pharmacodynamics of some medicinal products, for which dosage adjustment<br />may be necessary (examples include theophylline, warfarin and insulin). As smoking induces CYP1A2,<br />smoking cessation may result in an increase of plasma levels of CYP1A2 substrates.<br />Neuropsychiatric symptoms<br />Changes in behaviour or thinking, anxiety, psychosis, mood swings, aggressive behaviour, depression,<br />suicidal ideation and behaviour and suicide attempts have been reported in patients attempting to quit<br />smoking with CIMUQUIT in the post-marketing experience.<br />A large randomised, double-blind, active and placebo-controlled study was conducted to compare the<br />risk of serious neuropsychiatric events in patients with and without a history of psychiatric disorder<br />treated for smoking cessation with varenicline, bupropion, nicotine replacement therapy patch (NRT)<br />or placebo.<br />The primary safety endpoint was a composite of neuropsychiatric adverse events that have been<br />reported in post-marketing experience.<br />The use of varenicline in patients with or without a history of psychiatric disorder was not associated<br />with an increased risk of serious neuropsychiatric adverse events in the composite primary endpoint<br />compared with placebo (see section 5.1 Pharmacodynamic properties - Study in Subjects with and<br />without a History of Psychiatric Disorder). Depressed mood, rarely including suicidal ideation and<br />suicide attempt, may be a symptom of nicotine withdrawal.<br />Clinicians should be aware of the possible emergence of serious neuropsychiatric symptoms in patients<br />attempting to quit smoking with or without treatment. If serious neuropsychiatric symptoms occur<br />whilst on varenicline treatment, patients should discontinue varenicline immediately and contact a<br />healthcare professional for re-evaluation of treatment.<br />History of psychiatric disorders<br />Smoking cessation, with or without pharmacotherapy, has been associated with exacerbation of<br />underlying psychiatric illness (e.g. depression).<br />CIMUQUIT smoking cessation studies have provided data in patients with a history of psychiatric<br />disorders (see section 5.1).<br />In a smoking cessation clinical trial, neuropsychiatric adverse events were reported more frequently in<br />patients with a history of psychiatric disorders compared to those without a history of psychiatric<br />disorders, regardless of treatment (see section 5.1).<br />Care should be taken with patients with a history of psychiatric illness and patients should be advised<br />accordingly.<br />Seizures<br />In clinical trials and post-marketing experience there have been reports of seizures in patients with or<br />without a history of seizures, treated with CIMUQUIT. CIMUQUIT should be used cautiously in<br />patients with a history of seizures or other conditions that potentially lower the seizure threshold.<br />Treatment discontinuation<br />At the end of treatment, discontinuation of CIMUQUIT was associated with an increase in irritability,<br />urge to smoke, depression, and/or insomnia in up to 3% of patients. The prescriber should inform the<br />patient accordingly and discuss or consider the need for dose tapering.<br />Cardiovascular events<br />Patients taking CIMUQUIT should be instructed to notify their doctor of new or worsening<br />cardiovascular symptoms and to seek immediate medical attention if they experience signs and<br />symptoms of myocardial infarction or stroke (see section 5.1).<br />Hypersensitivity reactions<br />There have been post-marketing reports of hypersensitivity reactions including angioedema in patients<br />treated with varenicline. Clinical signs included swelling of the face, mouth (tongue, lips, and gums),<br />neck (throat and larynx) and extremities. There were rare reports of life-threatening angioedema<br />requiring urgent medical attention due to respiratory compromise. Patients experiencing these<br />symptoms should discontinue treatment with varenicline and contact a health care provider<br />immediately.<br />Cutaneous reactions<br />There have also been post-marketing reports of rare but severe cutaneous reactions, including StevensJohnson Syndrome and Erythema Multiforme in patients using varenicline. As these skin reactions can<br />be life threatening, patients should discontinue treatment at the first sign of rash or skin reaction and<br />contact a healthcare provider immediately.<br />Excipient information<br />This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially<br />&#39;sodium free&#39;.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on varenicline characteristics and clinical experience to date, CIMUQUIT has no clinically<br />meaningful drug interactions. No dosage adjustment of CIMUQUIT or co-administered medicinal<br />products listed below is recommended.<br />In vitro studies indicate that varenicline is unlikely to alter the pharmacokinetics of compounds that are<br />primarily metabolised by cytochrome P450 enzymes.<br />Furthermore, since metabolism of varenicline represents less than 10% of its clearance, active<br />substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of<br />varenicline (see section 5.2) and therefore a dose adjustment of CIMUQUIT would not be required.<br />In vitro studies demonstrate that varenicline does not inhibit human renal transport proteins at<br />therapeutic concentrations. Therefore, active substances that are cleared by renal secretion (e.g.,<br />metformin - see below) are unlikely to be affected by varenicline.<br />Metformin<br />Varenicline did not affect the pharmacokinetics of metformin. Metformin had no effect on varenicline<br />pharmacokinetics.<br />Cimetidine<br />Co-administration of cimetidine, with varenicline increased the systemic exposure of varenicline by<br />29% due to a reduction in varenicline renal clearance. No dosage adjustment is recommended based on<br />concomitant cimetidine administration in subjects with normal renal function or in patients with mild<br />to moderate renal impairment. In patients with severe renal impairment, the concomitant use of<br />cimetidine and varenicline should be avoided.<br />Digoxin<br />Varenicline did not alter the steady-state pharmacokinetics of<br />digoxin.<br />Warfarin<br />Varenicline did not alter the pharmacokinetics of warfarin. Prothrombin time (INR) was not affected<br />by varenicline. Smoking cessation itself may result in changes to warfarin pharmacokinetics (see<br />section 4.4).<br />Alcohol<br />There are limited clinical data on any potential interaction between alcohol and varenicline. There have<br />been post marketing reports of increased intoxicating effects of alcohol in patients treated with<br />varenicline. A causal relationship between these events and varenicline use has not been established.<br />Use with other therapies for smoking cessation<br />Bupropion<br />Varenicline did not alter the steady-state pharmacokinetics of bupropion.<br />Nicotine replacement therapy (NRT)<br />When varenicline and transdermal NRT were co-administered to smokers for 12 days, there was a<br />statistically significant decrease in average systolic blood pressure (mean 2.6 mmHg) measured on the<br />final day of the study. In this study, the incidence of nausea, headache, vomiting, dizziness, dyspepsia,<br />and fatigue was greater for the combination than for NRT alone.<br />Safety and efficacy of CIMUQUIT in combination with other smoking cessation therapies have not been<br />studied.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />A moderate amount of data on pregnant women indicated no malformative or foetal/neonatal toxicity<br />of varenicline (see section 5.1).<br />Animal studies have shown reproductive toxicity (see section 5.3). As a precautionary measure, it is<br />preferable to avoid the use of varenicline during pregnancy (see section 5.1).<br />Breast-feeding<br />It is unknown whether varenicline is excreted in human breast milk. Animal studies suggest that<br />varenicline is excreted in breast milk. A decision on whether to continue/discontinue breast-feeding or<br />to continue/discontinue therapy with CIMUQUIT should be made taking into account the benefit of<br />breast-feeding to the child and the benefit of CIMUQUIT therapy to the woman.<br />Fertility<br />There are no clinical data on the effects of varenicline on fertility.<br />Non-clinical data revealed no hazard for humans based on standard male and female fertility studies in<br />the rat (see section 5.3).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CIMUQUIT may have a minor or moderate influence on the ability to drive and use machines.<br />CIMUQUIT may cause dizziness, somnolence and transient loss of consciousness, and therefore may<br />influence the ability to drive and use machines. Patients are advised not to drive, operate complex<br />machinery or engage in other potentially hazardous activities until it is known whether this medicinal<br />product affects their ability to perform these activities.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Smoking cessation with or without treatment is associated with various symptoms. For example,<br />dysphoric or depressed mood; insomnia, irritability, frustration or anger; anxiety; difficulty<br />concentrating; restlessness; decreased heart rate; increased appetite or weight gain have been reported in<br />patients attempting to stop smoking. No attempt has been made in either the design or the analysis of<br />the CIMUQUIT studies to distinguish between adverse reactions associated with study drug treatment<br />or those possibly associated with nicotine withdrawal. Adverse drug reactions are based on evaluation<br />of data from pre-marketing phase 2-3 studies and updated based on pooled data from 18 placebocontrolled pre- and post-marketing studies, including approximately 5,000 patients treated with<br />varenicline.<br />In patients treated with the recommended dose of 1 mg twice daily following an initial titration period<br />the adverse event most commonly reported was nausea (28.6%). In the majority of cases nausea<br />occurred early in the treatment period, was mild to moderate in severity and seldom resulted in<br />discontinuation.<br />Tabulated summary of adverse reactions<br />In the table below all adverse reactions, which occurred at an incidence greater than placebo are listed<br />by system organ class and frequency (very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon<br />(&ge; 1/1,000 to &lt; 1/100) and rare (&ge; 1/10,000 to &lt; 1/1,000)). Within each frequency grouping, undesirable<br />effects are presented in order of decreasing seriousness.</p><table><tbody><tr><td>System Organ Class</td><td>Adverse Drug Reactions</td></tr><tr><td>Infections and infestations</td></tr><tr><td>Very common</td><td>Nasopharyngitis</td></tr><tr><td>Common</td><td>Bronchitis, sinusitis</td></tr><tr><td>Uncommon</td><td>Fungal infection, viral infection</td></tr><tr><td>Blood and lymphatic system disorders</td></tr><tr><td>Rare</td><td>Platelet count decreased</td></tr><tr><td>Metabolism and nutrition disorders</td></tr><tr><td>Common</td><td>Weight increased, decreased appetite, increased appetite</td></tr><tr><td>Uncommon</td><td>Hyperglycaemia</td></tr><tr><td>Rare</td><td>Diabetes mellitus, polydipsia</td></tr><tr><td>Psychiatric disorders</td></tr><tr><td>Very common</td><td>Abnormal dreams, insomnia</td></tr><tr><td>Uncommon</td><td>Suicidal ideation, aggression, panic reaction, thinking abnormal,<br />restlessness, mood swings, depression*, anxiety*, hallucinations*,<br />libido increased, libido decreased</td></tr><tr><td>Rare</td><td>Psychosis, somnambulism, abnormal behaviour, dysphoria,<br />bradyphrenia</td></tr><tr><td>Nervous system disorders</td></tr><tr><td>Very common</td><td>Headache</td></tr><tr><td>Common</td><td>Somnolence, dizziness, dysgeusia</td></tr><tr><td>Uncommon</td><td>Seizure, tremor, lethargy, hypoaesthesia</td></tr><tr><td>Rare</td><td>Cerebrovascular accident, hypertonia, dysarthria, coordination<br />abnormal, hypogeusia, circadian rhythm sleep disorder</td></tr><tr><td>Not known</td><td>Transient loss of consciousness</td></tr><tr><td>Eye disorders</td></tr><tr><td>Uncommon</td><td>Conjunctivitis, eye pain</td></tr><tr><td>Rare</td><td>Scotoma, scleral discolouration, mydriasis, photophobia, myopia,<br />lacrimation increased</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>Ear and labyrinth disorders</td></tr><tr><td>Uncommon</td><td>Tinnitus</td></tr><tr><td>Cardiac disorders</td></tr><tr><td>Uncommon</td><td>Myocardial infarction, angina pectoris, tachycardia, palpitations, heart<br />rate increased</td></tr><tr><td>Rare</td><td>Atrial fibrillation, electrocardiogram ST segment depression,<br />electrocardiogram T wave amplitude decreased</td></tr><tr><td>Vascular disorders</td></tr><tr><td>Uncommon</td><td>Blood pressure increased, hot flush</td></tr><tr><td>Respiratory, thoracic and mediastinal disorders</td></tr><tr><td>Common</td><td>Dyspnoea, cough</td></tr><tr><td>Uncommon</td><td>Upper respiratory tract inflammation, respiratory tract congestion,<br />dysphonia, rhinitis allergic, throat irritation, sinus congestion, upper<br />airway cough syndrome, rhinorrhoea</td></tr><tr><td>Rare</td><td>Laryngeal pain, snoring</td></tr><tr><td>Gastrointestinal disorders</td></tr><tr><td>Very common</td><td>Nausea</td></tr><tr><td>Common</td><td>Gastrooesophageal reflux disease, vomiting, constipation, diarrhoea,<br />abdominal distension, abdominal pain, toothache, dyspepsia,<br />flatulence, dry mouth</td></tr><tr><td>Uncommon</td><td>Haematochezia, gastritis, change of bowel habit, eructation, aphthous<br />stomatitis, gingival pain</td></tr><tr><td>Rare</td><td>Haematemesis, abnormal faeces, tongue coated</td></tr><tr><td>Skin and subcutaneous tissue disorders</td></tr><tr><td>Common</td><td>Rash, pruritus</td></tr><tr><td>Uncommon</td><td>Erythema, acne, hyperhidrosis, night sweats</td></tr><tr><td>Rare</td><td>Severe cutaneous reactions, including Stevens Johnson Syndrome and<br />Erythema Multiforme, angioedema</td></tr><tr><td>Musculoskeletal and connective tissue disorders</td></tr><tr><td>Common</td><td>Arthralgia, myalgia, back pain</td></tr><tr><td>Uncommon</td><td>Muscle spasms, musculoskeletal chest pain</td></tr><tr><td>Rare</td><td>Joint stiffness, costochondritis</td></tr><tr><td>Renal and urinary disorders</td></tr><tr><td>Uncommon</td><td>Pollakiuria, nocturia</td></tr><tr><td>Rare</td><td>Glycosuria, polyuria</td></tr><tr><td>Reproductive system and breast disorders</td></tr><tr><td>Uncommon</td><td>Menorrhagia</td></tr><tr><td>Rare</td><td>Vaginal discharge, sexual dysfunction</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>General disorders and administration site conditions</td></tr><tr><td>Common</td><td>Chest pain, fatigue</td></tr><tr><td>Uncommon</td><td>Chest discomfort, influenza like illness, pyrexia, asthenia, malaise</td></tr><tr><td>Rare</td><td>Feeling cold, cyst</td></tr><tr><td>Investigations</td></tr><tr><td>Common</td><td>Liver function test abnormal</td></tr><tr><td>Rare</td><td>Semen analysis abnormal, C-reactive protein increased, blood calcium<br />decreased</td></tr><tr><td>* Frequencies are estimated from a post-marketing, observational cohort study</td></tr></tbody></table><p>To report any side effect(s):</p><p>&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</p><p><br />&bull; United Arab Emirates</p><p>Pharmacovigilance &amp; Medical Device section<br />- P.O.Box: 1853<br />- Tel: 80011111<br />- Email : pv@mohap.gov.ae<br />- Drug Department Ministry of Health &amp; Prevention, Dubai, UAE<br />&nbsp;</p><p>&bull; Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No cases of overdose were reported in pre-marketing clinical trials.<br />In case of overdose, standard supportive measures should be instituted as required.<br />Varenicline has been shown to be dialyzed in patients with end stage renal disease (see section 5.2),<br />however, there is no experience in dialysis following overdose.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other nervous system drugs; Drugs used in addictive disorders; Drugs used in<br />nicotine dependence, ATC code: N07BA03<br />Mechanism of action<br />Varenicline binds with high affinity and selectivity at the &alpha;4&beta;2 neuronal nicotinic acetylcholine<br />receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower<br />intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine.<br />Pharmacovigilance &amp; Medical Device section<br />- P.O.Box: 1853<br />- Tel: 80011111<br />- Email : pv@mohap.gov.ae<br />- Drug Department Ministry of Health &amp; Prevention, Dubai, UAE<br />Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline<br />binds to the &alpha;4&beta;2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated<br />activity, but at a significantly lower level than nicotine. Nicotine competes for the same human &alpha;4&beta;2<br />nAChR binding site for which varenicline has higher affinity.<br />Therefore, varenicline can effectively block nicotine&#39;s ability to fully activate &alpha;4&beta;2 receptors and the<br />mesolimbic dopamine system, the neuronal mechanism underlying reinforcement and reward<br />experienced upon smoking. Varenicline is highly selective and binds more potently to the &alpha;4&beta;2<br />receptor subtype (Ki=0.15 nM) than to other common nicotinic receptors (&alpha;3&beta;4 Ki=84 nM, &alpha;7 Ki=<br />620 nM, &alpha;1&beta;&gamma;&delta; Ki= 3,400 nM), or to non-nicotinic receptors and transporters (Ki &gt; 1&micro;M, except to 5-<br />HT3 receptors: Ki=350 nM).<br />Pharmacodynamic effects<br />The efficacy of CIMUQUIT in smoking cessation is a result of varenicline&#39;s partial agonist activity at<br />the &alpha;4&beta;2 nicotinic receptor where its binding produces an effect sufficient to alleviate symptoms of<br />craving and withdrawal (agonist activity), while simultaneously resulting in a reduction of the<br />rewarding and reinforcing effects of smoking by preventing nicotine binding to &alpha;4&beta;2 receptors<br />(antagonist activity).<br />Clinical efficacy and safety<br />Smoking cessation therapies are more likely to succeed for patients who are motivated to stop<br />smoking and who are provided with additional advice and support.<br />The efficacy of CIMUQUIT in smoking cessation was demonstrated in 3 clinical trials involving<br />chronic cigarette smokers (&ge; 10 cigarettes per day). Two thousand six hundred nineteen (2619)<br />patients received CIMUQUIT 1 mg BID (titrated during the first week), 669 patients received<br />bupropion 150 mg BID (also titrated) and 684 patients received placebo.<br />Comparative clinical studies<br />Two identical double-blind clinical trials prospectively compared the efficacy of CIMUQUIT (1 mg<br />twice daily), sustained release bupropion (150 mg twice daily) and placebo in smoking cessation. In<br />these 52-week duration studies, patients received treatment for 12 weeks, followed by a 40-week nontreatment phase.<br />The primary endpoint of the two studies was the carbon monoxide (CO) confirmed, 4-week<br />continuous quit rate (4W- CQR) from week 9 through week 12. The primary endpoint for<br />CIMUQUIT demonstrated statistical superiority to bupropion and placebo.<br />After the 40 week non-treatment phase, a key secondary endpoint for both studies was the Continuous<br />Abstinence Rate (CA) at week 52. CA was defined as the proportion of all subjects treated who did<br />not smoke (not even a puff of a cigarette) from Week 9 through Week 52 and did not have an exhaled<br />CO measurement of &gt; 10 ppm.<br />The 4W-CQR (weeks 9 through 12) and CA rate (weeks 9 through 52) from studies 1 and 2 are<br />included in the following table:</p><table><tbody><tr><td>Study 1 (n=1022)</td><td>Study 2 (n=1023)</td></tr><tr><td>4W CQR</td><td>CA Wk 9-<br />52</td><td>4W CQR</td><td>CA Wk 9-<br />52</td></tr><tr><td>CIMUQUIT</td><td>44.4%</td><td>22.1%</td><td>44.0%</td><td>23.0%</td></tr><tr><td>Bupropion</td><td>29.5%</td><td>16.4%</td><td>30.0%</td><td>15.0%</td></tr><tr><td>Placebo</td><td>17.7%</td><td>8.4%</td><td>17.7%</td><td>10.3%</td></tr><tr><td>Odds ratio<br />CIMUQUIT vs. placebo</td><td>3.91<br />p &lt; 0.0001</td><td>3.13<br />p &lt; 0.0001</td><td>3.85<br />p &lt; 0.0001</td><td>2.66<br />p &lt; 0.0001</td></tr><tr><td>Odds ratio<br />CIMUQUIT vs. bupropion</td><td>1.96<br />p &lt; 0.0001</td><td>1.45<br />p = 0.0640</td><td>1.89<br />p &lt; 0.0001</td><td>1.72<br />p = 0.0062</td></tr></tbody></table><p>Patient-reported craving, withdrawal and reinforcing effects of smoking<br />Across both Studies 1 and 2 during active treatment, craving and withdrawal were significantly reduced<br />in patients randomised to CIMUQUIT in comparison with placebo. CIMUQUIT also significantly<br />reduced reinforcing effects of smoking that can perpetuate smoking behaviour in patients who smoke<br />during treatment compared with placebo. The effect of varenicline on craving, withdrawal and reinforcing<br />effects of smoking were not measured during the non-treatment long-term follow-up phase.<br />Maintenance of abstinence study<br />The third study assessed the benefit of an additional 12 weeks of CIMUQUIT therapy on the maintenance<br />of abstinence. Patients in this study (n=1,927) received open-label CIMUQUIT 1 mg twice daily for 12<br />weeks. Patients who stopped smoking by Week 12 were then randomised to receive either CIMUQUIT (1<br />mg twice daily) or placebo for an additional 12 weeks for a total study duration of 52 weeks.<br />The primary study endpoint was the CO-confirmed continuous abstinence rate from week 13 through<br />week 24 in the double-blind treatment phase. A key secondary endpoint was the continuous abstinence<br />(CA) rate for week 13 through week 52.<br />This study showed the benefit of additional 12-week treatment with CIMUQUIT 1 mg twice daily for the<br />maintenance of smoking cessation compared to placebo; superiority to placebo for CA was maintained<br />through week 52. The key results are summarised in the following table:<br />Continuous Abstinence Rates in Subjects Treated with Cimuquit versus Placebo</p><table><tbody><tr><td>CIMUQUIT<br />n=602</td><td>Placebo<br />n=604</td><td>Difference<br />(95% CI)</td><td>Odds ratio<br />(95% CI)</td></tr><tr><td>CA* wk 13-24</td><td>70.6%</td><td>49.8%</td><td>20.8%<br />(15.4%, 26.2%)</td><td>2.47<br />(1.95, 3.15)</td></tr><tr><td>CA* wk 13-52</td><td>44.0%</td><td>37.1%</td><td>6.9%<br />(1.4%, 12.5%)</td><td>1.35<br />(1.07, 1.70)</td></tr></tbody></table><p>*CA: Continuous Abstinence Rate<br />There is currently limited clinical experience with the use of CIMUQUIT among black people to determine<br />clinical efficacy.<br />Flexible quit date between weeks 1 and 5<br />The efficacy and safety of varenicline has been evaluated in smokers who had the flexibility of quitting<br />between weeks 1 and 5 of treatment. In this 24-week study, patients received treatment for 12 weeks<br />followed by a 12 week non-treatment follow up phase. The 4 week (week 9-12) CQR for varenicline and<br />placebo was 53.9% and 19.4%, respectively (difference=34.5%, 95% CI: 27.0% - 42.0%) and the CA<br />week 9-24 was 35.2% (varenicline) vs. 12.7% (placebo) (difference=22.5%, 95% CI: 15.8% - 29.1%).<br />Patients who are not willing or able to set the target quit date within 1-2 weeks, could be offered to start<br />treatment and then choose their own quit date within 5 weeks.<br />Study in subjects re-treated with CIMUQUIT<br />CIMUQUIT was evaluated in a double-blind, placebo-controlled trial of 494 patients who had made a<br />previous attempt to quit smoking with CIMUQUIT, and either did not succeed in quitting or relapsed<br />after treatment. Subjects who experienced an adverse event of a concern during previous treatment were<br />excluded. Subjects were randomised 1:1 to CIMUQUIT 1 mg twice daily (N=249) or placebo (N=245)<br />for 12 weeks of treatment and followed for up to 40 weeks post- treatment. Patients included in this<br />study had taken CIMUQUIT for a smoking-cessation attempt in the past (for a total treatment duration of<br />a minimum of two weeks), at least three months prior to study entry, and had been smoking for at least<br />four weeks.<br />Patients treated with CIMUQUIT had a superior rate of CO-confirmed abstinence during weeks 9 through<br />12 and from weeks 9 through 52 compared to subjects treated with placebo. The key results are<br />summarised in the following table:<br />Continuous Abstinence Rates in Subjects Treated with Cimuquit versus Placebo</p><table><tbody><tr><td>CIMUQUIT</td><td>Placebo</td><td>Odds ratio (95% CI),</td></tr><tr><td>n=249</td><td>n=245</td><td>p value</td></tr><tr><td>CA* wk 9-12</td><td>45.0%</td><td>11.8%</td><td>7.08 (4.34,<br />11.55),<br />p&lt;0.0001</td></tr><tr><td>CA* wk 9-52</td><td>20.1%</td><td>3.3%</td><td>9.00 (3.97,<br />20.41),<br />p&lt;0.0001</td></tr></tbody></table><p>*CA: Continuous Abstinence Rate<br />Gradual approach to quitting smoking<br />CIMUQUIT was evaluated in a 52-week double-blind placebo-controlled study of 1,510 subjects who<br />were not able or willing to quit smoking within four weeks, but were willing to gradually reduce their<br />smoking over a 12 week period before quitting. Subjects were randomised to either CIMUQUIT 1 mg<br />twice daily (n=760) or placebo (n=750) for 24 weeks and followed up post-treatment through week 52.<br />Subjects were instructed to reduce the number of cigarettes smoked by at least 50 percent by the end of<br />the first four weeks of treatment, followed by a further 50 percent reduction from week four to week<br />eight of treatment, with the goal of reaching complete abstinence by 12 weeks. After the initial 12-week<br />reduction phase, subjects continued treatment for another 12 weeks. Subjects treated with CIMUQUIT<br />had a significantly higher Continuous Abstinence Rate compared with placebo; the key results are<br />summarised in the following table:<br />Continuous Abstinence Rates in Subjects Treated with Cimuquit versus Placebo</p><table><tbody><tr><td>CIMUQUIT<br />n=760</td><td>Placebo<br />n=750</td><td>Odds ratio (95% CI),<br />p value</td></tr><tr><td>CA* wk 15-24</td><td>32.1%</td><td>6.9%</td><td>8.74 (6.09, 12.53),<br />p&lt;0.0001</td></tr><tr><td>CA* wk 21-52</td><td>27.0%</td><td>9.9%</td><td>4.02 (2.94, 5.50),<br />p&lt;0.0001</td></tr><tr><td>*CA: Continuous Abstinence Rate</td></tr></tbody></table><p>The CIMUQUIT safety profile in this study was consistent with that of pre-marketing studies.<br />Subjects with cardiovascular disease<br />CIMUQUIT was evaluated in a randomised, double-blind, placebo-controlled study of subjects with<br />stable, cardiovascular disease (other than, or in addition to, hypertension) that had been diagnosed for<br />more than 2 months. Subjects were randomised to CIMUQUIT 1 mg twice daily (n=353) or placebo<br />(n=350) for 12 weeks and then were followed for 40 weeks post-treatment. The 4 week CQR for<br />varenicline and placebo was 47.3% and 14.3%, respectively and the CA week 9-52 was 19.8%<br />(varenicline) vs. 7.4% (placebo).<br />Deaths and serious cardiovascular events were adjudicated by a blinded, committee. The following<br />adjudicated events occurred with a frequency &ge; 1% in either treatment group during treatment (or in the<br />30-day period after treatment): nonfatal myocardial infarction (1.1% vs. 0.3% for CIMUQUIT and<br />placebo, respectively), and hospitalisation for angina pectoris (0.6% vs. 1.1%). During non-treatment<br />follow up to 52 weeks, the adjudicated events included the need for coronary revascularisation (2.0% vs.<br />0.6%), hospitalisation for angina pectoris (1.7% vs. 1.1%), and a new diagnosis of peripheral vascular<br />disease (PVD) or admission for a PVD procedure (1.4% vs. 0.6%). Some of the patients requiring<br />coronary revascularisation underwent the procedure as part of the management of nonfatal MI and<br />hospitalisation for angina.<br />Cardiovascular death occurred in 0.3% of patients in the CIMUQUIT arm and 0.6% of patients in the<br />placebo arm over the course of the 52-week study.<br />A meta-analysis of 15 clinical trials of &ge; 12 weeks treatment duration, including 7002 patients (4190<br />CIMUQUIT, 2812 placebo), was conducted to systematically assess the cardiovascular safety of<br />CIMUQUIT. The study in patients with stable cardiovascular disease described above was included in<br />the meta-analysis.<br />The key cardiovascular safety analysis included occurrence and timing of a composite endpoint of<br />Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, nonfatal MI, and<br />nonfatal stroke. These events included in the endpoint were adjudicated by a blinded, independent<br />committee. Overall, a small number of MACE occurred during treatment in the trials included in the<br />meta-analysis (CIMUQUIT 7 [0.17%]; placebo 2 [0.07%]).<br />Additionally, a small number of MACE occurred up to 30 days after treatment (CIMUQUIT 13 [0.31%];<br />placebo 6 [0.21%]).<br />The meta-analysis showed that exposure to CIMUQUIT resulted in a hazard ratio for MACE of 2.83<br />(95% confidence interval from 0.76 to 10.55, p=0.12) for patients during treatment and 1.95 (95%<br />confidence interval from 0.79 to 4.82, p=0.15) for patients up to 30 days after treatment. These are<br />equivalent to an estimated increase of 6.5 MACE events and 6.3 MACE events per 1,000 patient-years,<br />respectively of exposure. The hazard ratio for MACE was higher in patients with cardiovascular risk<br />factors in addition to smoking compared with that in patients without cardiovascular risk factors other<br />than smoking. There were similar rates of all-cause mortality (CIMUQUIT 6 [0.14%]; placebo 7<br />[0.25%]) and cardiovascular mortality (CIMUQUIT 2 [0.05%]; placebo 2 [0.07%]) in the CIMUQUIT<br />arms compared with the placebo arms in the meta-analysis.<br />Cardiovascular safety assessment study in subjects with and without a history of psychiatric disorder<br />The cardiovascular (CV) safety of CIMUQUIT was evaluated in the Study in Subjects with and without a<br />History of Psychiatric Disorder (parent study; see section 5.1 - Neuropsychiatric safety) and its nontreatment extension, the Cardiovascular Safety Assessment Study, which enrolled 4595 of the 6293<br />subjects who completed the parent study (N=8058) and followed them through week 52. Of all subjects<br />treated in the parent study, 1749 (21.7%) had a medium CV risk and 644 (8.0%) had a high CV risk, as<br />defined by Framingham score.<br />The primary CV endpoint was the time to major adverse cardiovascular events (MACE), defined as<br />cardiovascular death, non-fatal myocardial infarction or non-fatal stroke during treatment. Deaths and<br />cardiovascular events were adjudicated by a blinded, independent committee.<br />The following table shows the incidence of MACE and Hazard Ratios vs placebo for all treatment<br />groups during treatment, and cumulative for treatment plus 30 days and through end of study.</p><table><tbody><tr><td>CIMUQUIT<br />N=2016</td><td>Bupropion<br />N=2006</td><td>NRT<br />N=2022</td><td>Placebo<br />N=2014</td></tr><tr><td>During treatment</td></tr><tr><td>MACE, n (%)</td><td>1 (0.05)</td><td>2 (0.10)</td><td>1 (0.05)</td><td>4 (0.20)</td></tr><tr><td>Hazard Ratio<br />(95% CI) vs<br />placebo</td><td>0.29 (0.05, 1.68)</td><td>0.50 (0.10, 2.50)</td><td>0.29 (0.05, 1.70)</td></tr><tr><td>During treatment plus 30 days</td></tr><tr><td>MACE, n (%)</td><td>1 (0.05)</td><td>2 (0.10)</td><td>2 (0.10)</td><td>4 (0.20)</td></tr><tr><td>Hazard Ratio<br />(95% CI) vs<br />placebo</td><td>0.29 (0.05, 1.70)</td><td>0.51 (0.10, 2.51)</td><td>0.50 (0.10, 2.48)</td></tr><tr><td>Through end of study</td></tr><tr><td>MACE, n (%)</td><td>3 (0.15)</td><td>9 (0.45)</td><td>6 (0.30)</td><td>8 (0.40)</td></tr><tr><td>Hazard Ratio<br />(95% CI) vs<br />placebo</td><td>0.39 (0.12, 1.27)</td><td>1.09 (0.42, 2.83)</td><td>0.75 (0.26, 2.13)</td></tr></tbody></table><p>The use of CIMUQUIT, bupropion, and NRT was not associated with an increased risk of CV AEs in<br />smokers treated for up to 12 weeks and followed for up to 1 year compared to placebo, although because<br />of the relatively low number of events overall, an association cannot be entirely ruled out.<br />Subjects with mild-moderate chronic obstructive pulmonary disease (COPD)<br />The efficacy and safety of CIMUQUIT (1 mg twice daily) for smoking cessation in subjects with mildmoderate COPD was demonstrated in a randomised double-blind placebo-controlled clinical trial. In this<br />52-week duration study, patients received treatment for 12 weeks, followed by a 40-week non-treatment<br />follow-up phase. The primary endpoint of the study was the CO-confirmed, 4-week Continuous Quit<br />Rate (4W CQR) from week 9 through week 12 and a key secondary endpoint was the Continuous<br />Abstinence (CA) from Week 9 through Week 52. The safety profile of varenicline was comparable to<br />what was reported in other trials in the general population, including pulmonary safety.<br />The results for the 4W CQR (weeks 9 through 12) and CA rate (weeks 9 through 52) are shown in the<br />following table:</p><table><tbody><tr><td>4W CQR</td><td>CA Wk 9-52</td></tr><tr><td>CIMUQUIT, (n = 248)</td><td>42.3%</td><td>18.5%</td></tr><tr><td>Placebo, (n = 251)</td><td>8.8%</td><td>5.6%</td></tr><tr><td>Odds ratio<br />(CIMUQUIT vs. Placebo)</td><td>8.40<br />p &lt; 0.0001</td><td>4.04<br />p &lt; 0.0001</td></tr></tbody></table><p>Study in subjects with a history of major depressive disorder<br />The efficacy of varenicline was confirmed in a randomised placebo-controlled trial in 525 subjects with a<br />history of major depression in the past two years or under current stable treatment. The cessation rates in<br />this population were similar to those reported in the general population. Continuous abstinence rate<br />between weeks 9-12 was 35.9% in the varenicline treatment group versus 15.6% in the placebo group<br />(OR 3.35 (95% CI 2.16-5.21)) and between weeks 9-52 was 20.3% versus 10.4% respectively (OR 2.36<br />(95% CI 1.40-3.98)). The most common adverse events (&ge; 10%) in subjects taking varenicline were<br />nausea (27.0% vs. 10.4% on placebo), headache (16.8% vs. 11.2%), abnormal dreams (11.3% vs. 8.2%),<br />insomnia (10.9% vs. 4.8%) and irritability (10.9% vs. 8.2%). Psychiatric scales showed no differences<br />between the varenicline and placebo groups and no overall worsening of depression, or other psychiatric<br />symptoms, during the study in either treatment group.<br />Study in subjects with stable schizophrenia or schizoaffective disorder<br />Varenicline safety and tolerability was assessed in a double-blind study of 128 smokers with stable<br />schizophrenia or schizoaffective disorder, on antipsychotic medication, randomised 2:1 to varenicline (1<br />mg twice daily) or placebo for 12 weeks with 12-week non-drug follow-up.<br />The most common adverse events in subjects taking varenicline were nausea (23.8% vs. 14.0% on<br />placebo), headache (10.7% vs. 18.6% on placebo) and vomiting (10.7% vs. 9.3% on placebo). Among<br />reported neuropsychiatric adverse events, insomnia was the only event reported in either treatment group<br />in &ge; 5% of subjects at a rate higher in the varenicline group than in placebo (9.5% vs. 4.7%).<br />Overall, there was no worsening of schizophrenia in either treatment group as measured by psychiatric<br />scales and there were no overall changes in extra-pyramidal signs. In the varenicline group compared to<br />placebo, a higher proportion of subjects reported suicidal ideation or behaviour prior to enrolment<br />(lifetime history) and after the end of active treatment period (on Days 33 to 85 after the last dose of<br />treatment). During the active treatment period, the incidence of suicide- related events was similar<br />between the varenicline-treated and the placebo-treated subjects (11 vs. 9.3%, respectively). The<br />percentage of subjects with suicide-related events in the active treatment phase compared to posttreatment phase was unchanged in the varenicline group; in the placebo group, this percentage was lower<br />in the post-treatment phase. Although there were no completed suicides, there was one suicidal attempt<br />in a varenicline-treated subject whose lifetime history included several similar attempts. The limited data<br />available from this single smoking cessation study are not sufficient to allow for definitive conclusions to<br />be drawn about the safety in patients with schizophrenia or schizoaffective disorder.<br />Neuropsychiatric Safety Study in Subjects with and without a History of Psychiatric Disorder:<br />Varenicline was evaluated in a randomised, double-blind, active and placebo-controlled study that<br />included subjects with a history of psychiatric disorder (psychiatric cohort, N=4074) and subjects<br />without a history of psychiatric disorder (non-psychiatric cohort, N=3984). Subjects aged 18-75 years,<br />smoking 10 or more cigarettes per day were randomised 1:1:1:1 to varenicline 1 mg BID, bupropion SR<br />150 mg BID, nicotine replacement therapy patch (NRT) 21 mg/day with taper or placebo for a treatment<br />period of 12 weeks; they were then followed for another 12 weeks post-treatment.<br />The primary safety endpoint was a composite of the following neuropsychiatric (NPS) adverse events:<br />severe events of anxiety, depression, feeling abnormal, or hostility, and/or moderate or severe events of<br />agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis,<br />suicidal ideation, suicidal behaviour or completed suicide.<br />The following table shows the rates of the composite NPS adverse event primary endpoint by treatment<br />group and the risk differences (RDs) (95% CI) vs placebo in the non-psychiatric cohort.<br />In addition, the table shows the subset of the composite NPS AE endpoint of severe intensity:</p><table><tbody><tr><td>Non-psychiatric<br />Cohort N=3984</td></tr><tr><td>Vareniclin<br />e</td><td>Bupropio<br />n</td><td>NRT</td><td>Placebo</td></tr><tr><td>Number of Patients Treated</td><td>990</td><td>989</td><td>1006</td><td>999</td></tr><tr><td>Composite NPS AE Primary<br />Endpoint, n (%)</td><td>13 (1.3)</td><td>22 (2.2)</td><td>25 (2.5)</td><td>24 (2.4)</td></tr><tr><td>RD (95% CI) vs Placebo</td><td>-1.28<br />(-2.40, -0.15)</td><td>-0.08<br />(-1.37, 1.21)</td><td>-0.21<br />(-1.54,1.12)</td></tr><tr><td>Composite NPS AE<br />Endpoint of severe intensity<br />n (%)</td><td>1 (0.1)</td><td>4 (0.4)</td><td>3 (0.3)</td><td>5 (0.5)</td></tr></tbody></table><p>AE, adverse event; NRT=Nicotine replacement therapy patch<br />The rates of events in the composite endpoint were low across all treatment groups and were similar or<br />lower for each of the active treatments compared to placebo. The use of varenicline, bupropion and NRT<br />in the non-psychiatric cohort was not associated with a significantly increased risk of NPS adverse events<br />in the composite primary endpoint compared with placebo (95% CIs were lower than or included zero).<br />The percentage of subjects with suicidal ideation and/or behaviour based on the Columbia-Suicide Severity<br />Rating Scale (C-SSRS) was similar between the varenicline and placebo groups during treatment and in<br />the non- treatment follow-up, as shown in the following table:</p><table><tbody><tr><td>Non-psychiatric<br />Cohort N=3984</td></tr><tr><td>Varenicline<br />N=990<br />n (%)</td><td>Bupropion<br />N=989<br />n (%)</td><td>NRT<br />N=1006<br />n (%)</td><td>Placebo<br />N=999<br />n (%)</td></tr><tr><td>During treatment</td></tr><tr><td>Number assessed</td><td>988</td><td>983</td><td>996</td><td>995</td></tr><tr><td>Suicidal behaviour<br />and/or ideation</td><td>7 (0.7)</td><td>4 (0.4)</td><td>3 (0.3)</td><td>7 (0.7)</td></tr><tr><td>Suicidal behaviour</td><td>0</td><td>0</td><td>1 (0.1)</td><td>1 (0.1)</td></tr><tr><td>Suicidal ideation</td><td>7 (0.7)</td><td>4 (0.4)</td><td>3 (0.3)</td><td>6 (0.6)</td></tr><tr><td>During follow up</td></tr><tr><td>Number assessed</td><td>807</td><td>816</td><td>800</td><td>805</td></tr><tr><td>Suicidal behaviour<br />and/or ideation</td><td>3 (0.4)</td><td>2 (0.2)</td><td>3 (0.4)</td><td>4 (0.5)</td></tr><tr><td>Suicidal behaviour</td><td>0</td><td>1 (0.1)</td><td>0</td><td>0</td></tr><tr><td>Suicidal ideation</td><td>3 (0.4)</td><td>2 (0.2)</td><td>3 (0.4)</td><td>4 (0.5)</td></tr></tbody></table><p>NRT=Nicotine replacement therapy patch<br />There was one completed suicide, which occurred during treatment in a subject treated with placebo in<br />the non- psychiatric cohort.<br />The following table shows the rates of the composite NPS adverse event primary endpoint by treatment<br />group and the RDs (95% CI) vs placebo in the psychiatric cohort. The individual components of the<br />endpoint are also shown.<br />In addition, the table shows the subset of the composite NPS AE endpoint of severe intensity:</p><table><tbody><tr><td>Psychiatric<br />Cohort N=4074</td></tr><tr><td>Varenicline</td><td>Bupropion</td><td>NRT</td><td>Placebo</td></tr><tr><td>Number of Patients Treated</td><td>1026</td><td>1017</td><td>1016</td><td>1015</td></tr><tr><td>Composite NPS AE Primary<br />Endpoint, n (%)</td><td>67 (6.5)</td><td>68 (6.7)</td><td>53 (5.2)</td><td>50 (4.9)</td></tr><tr><td>RD (95% CI) vs Placebo</td><td>1.59<br />(-0.42, 3.59)</td><td>1.78<br />(-0.24, 3.81)</td><td>0.37<br />(-1.53, 2.26)</td></tr><tr><td>NPS AE Primary Endpoint<br />Components n (%):</td></tr><tr><td>Anxietya</td><td>5 (0.5)</td><td>4 (0.4)</td><td>6 (0.6)</td><td>2 (0.2)</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>Depressiona</td><td>6 (0.6)</td><td>4 (0.4)</td><td>7 (0.7)</td><td>6 (0.6)</td></tr><tr><td>Feeling abnormala</td><td>0</td><td>1 (0.1)</td><td>0</td><td>0</td></tr><tr><td>Hostilitya</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Agitationb</td><td>25 (2.4)</td><td>29 (2.9)</td><td>21 (2.1)</td><td>22 (2.2)</td></tr><tr><td>Aggressionb</td><td>14 (1.4)</td><td>9 (0.9)</td><td>7 (0.7)</td><td>8 (0.8)</td></tr><tr><td>Delusionsb</td><td>1 (0.1)</td><td>1 (0.1)</td><td>1 (0.1)</td><td>0</td></tr><tr><td>Hallucinationsb</td><td>5 (0.5)</td><td>4 (0.4)</td><td>2 (0.2)</td><td>2 (0.2)</td></tr><tr><td>Homicidal ideationb</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Maniab</td><td>7 (0.7)</td><td>9 (0.9)</td><td>3 (0.3)</td><td>6 (0.6)</td></tr><tr><td>Panicb</td><td>7 (0.7)</td><td>16 (1.6)</td><td>13 (1.3)</td><td>7 (0.7)</td></tr><tr><td>Paranoiab</td><td>1 (0.1)</td><td>0</td><td>0</td><td>2 (0.2)</td></tr><tr><td>Psychosisb</td><td>4 (0.4)</td><td>2 (0.2)</td><td>3 (0.3)</td><td>1 (0.1)</td></tr><tr><td>Suicidal behaviourb</td><td>1 (0.1)</td><td>1 (0.1)</td><td>0</td><td>1 (0.1)</td></tr><tr><td>Suicidal ideationb</td><td>5 (0.5)</td><td>2 (0.2)</td><td>3 (0.3)</td><td>2 (0.2)</td></tr><tr><td>Completed suicideb</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Composite NPS AE Endpoint<br />of severe intensity n (%)</td><td>14 (1.4)</td><td>14 (1.4)</td><td>14 (1.4)</td><td>13 (1.3)</td></tr></tbody></table><p>AE, adverse event; aGrade = severe intensity AE; bGrade = moderate and severe intensity AE;<br />NRT=Nicotine replacement therapy patch<br />There were more events reported in patients in the psychiatric cohort in each treatment group compared<br />with the non- psychiatric cohort, and the incidence of events in the composite endpoint was higher for<br />each of the active treatments compared to placebo. However, the use of varenicline, bupropion and NRT<br />in the psychiatric cohort was not associated with a significantly increased risk of NPS adverse events in<br />the composite primary endpoint compared with placebo (95% CIs included zero).<br />In the psychiatric cohort, the percentage of subjects with suicidal ideation and/or behaviour based on the<br />Columbia- Suicide Severity Rating Scale (C-SSRS) was similar between the varenicline and placebo<br />groups during treatment and in the non- treatment follow-up, as shown in the following table:</p><table><tbody><tr><td>Psychiatric Cohort<br />N=4074</td></tr><tr><td>Varenicline<br />N=1026<br />n (%)</td><td>Bupropion<br />N=1017<br />n (%)</td><td>NRT<br />N=1016<br />n (%)</td><td>Placebo<br />N=1015<br />n (%)</td></tr><tr><td>During treatment</td></tr><tr><td>Number assessed</td><td>1017</td><td>1012</td><td>1006</td><td>1006</td></tr><tr><td>Suicidal<br />behaviour<br />and/or ideation</td><td>27 (2.7)</td><td>15 (1.5)</td><td>20 (2.0)</td><td>25 (2.5)</td></tr><tr><td>Suicidal behaviour</td><td>0</td><td>1 (0.1)</td><td>0</td><td>2 (0.2)</td></tr><tr><td>Suicidal ideation</td><td>27 (2.7)</td><td>15 (1.5)</td><td>20 (2.0)</td><td>25 (2.5)</td></tr><tr><td>During follow up</td></tr><tr><td>Number assessed</td><td>833</td><td>836</td><td>824</td><td>791</td></tr><tr><td>Suicidal<br />behaviour<br />and/or ideation</td><td>14 (1.7)</td><td>4 (0.5)</td><td>9 (1.1)</td><td>11 (1.4)</td></tr><tr><td>Suicidal behaviour</td><td>1 (0.1)</td><td>0</td><td>1 (0.1)</td><td>1 (0.1)</td></tr><tr><td>Suicidal ideation</td><td>14 (1.7)</td><td>4 (0.5)</td><td>9 (1.1)</td><td>11 (1.4)</td></tr></tbody></table><p>NRT=Nicotine replacement therapy patch<br />There were no completed suicides reported in the psychiatric cohort.<br />The most commonly reported adverse events in subjects treated with varenicline in this study were similar<br />to those observed in premarketing studies.<br />In both cohorts, subjects treated with varenicline demonstrated statistical superiority of CO-confirmed<br />abstinence during weeks 9 through 12 and 9 through 24 compared to subjects treated with bupropion,<br />nicotine patch and placebo (please see table below).<br />The key efficacy results are summarised in the following table:</p><table><tbody><tr><td>Non-psychiatric<br />Cohort</td><td>Psychiatric Cohort</td></tr><tr><td>CA 9-12 n/N (%)</td></tr><tr><td>Varenicline</td><td>382/1005 (38.0%)</td><td>301/1032 (29.2%)</td></tr><tr><td>Bupropion</td><td>261/1001 (26.1%)</td><td>199/1033 (19.3%)</td></tr><tr><td>NRT</td><td>267/1013 (26.4%)</td><td>209/1025 (20.4%)</td></tr><tr><td>Placebo</td><td>138/1009 (13.7%)</td><td>117/1026 (11.4%)</td></tr><tr><td>Treatment Comparisons: Odds ratio (95% CI), p value</td></tr><tr><td>Varenicline vs Placebo</td><td>4.00 (3.20, 5.00),<br />P&lt;0.0001</td><td>3.24 (2.56, 4.11),<br />P&lt;0.0001</td></tr><tr><td>Bupropion vs Placebo</td><td>2.26 (1.80, 2.85),<br />P&lt;0.0001</td><td>1.87 (1.46, 2.39),<br />P&lt;0.0001</td></tr><tr><td>NRT vs Placebo</td><td>2.30 (1.83, 2.90),<br />P&lt;0.0001</td><td>2.00 (1.56, 2.55),<br />P&lt;0.0001</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>Varenicline vs Bupropion</td><td>1.77 (1.46, 2.14),<br />P&lt;0.0001</td><td>1.74 (1.41, 2.14),<br />P&lt;0.0001</td></tr><tr><td>Varenicline vs NRT</td><td>1.74 (1.43, 2.10),<br />P&lt;0.0001</td><td>1.62 (1.32, 1.99),<br />P&lt;0.0001</td></tr><tr><td>CA 9-24 n/N (%)</td></tr><tr><td>Varenicline</td><td>256/1005 (25.5%)</td><td>189/1032 (18.3%)</td></tr><tr><td>Bupropion</td><td>188/1001 (18.8%)</td><td>142/1033 (13.7%)</td></tr><tr><td>NRT</td><td>187/1013 (18.5%)</td><td>133/1025 (13.0%)</td></tr><tr><td>Placebo</td><td>106/1009 (10.5%)</td><td>85/1026 (8.3%)</td></tr><tr><td>Treatment Comparisons: Odds ratio (95% CI), p value</td></tr><tr><td>Varenicline vs Placebo</td><td>2.99 (2.33, 3.83),<br />P&lt;0.0001</td><td>2.50 (1.90, 3.29),<br />P&lt;0.0001</td></tr><tr><td>Bupropion vs Placebo</td><td>2.00 (1.54, 2.59),<br />P&lt;0.0001</td><td>1.77 (1.33, 2.36),<br />P&lt;0.0001</td></tr><tr><td>NRT vs Placebo</td><td>1.96 (1.51, 2.54),<br />P&lt;0.0001</td><td>1.65 (1.24, 2.20),<br />P=0.0007</td></tr><tr><td>Varenicline vs Bupropion</td><td>1.49 (1.20, 1.85),<br />P=0.0003</td><td>1.41 (1.11, 1.79),<br />P=0.0047</td></tr><tr><td>Varenicline vs NRT</td><td>1.52 (1.23, 1.89),<br />P=0.0001</td><td>1.51 (1.19, 1.93),<br />P=0.0008</td></tr></tbody></table><p>CA = continuous abstinence rate; CI = confidence interval; NRT=Nicotine replacement therapy patch<br />Neuropsychiatric Safety Meta-analyses and Observational Studies:<br />Analyses of clinical trial data did not show evidence of an increased risk of serious neuropsychiatric<br />events with varenicline compared to placebo. In addition, independent observational studies have not<br />supported an increased risk of serious neuropsychiatric events in patients treated with varenicline<br />compared to patients prescribed nicotine replacement therapy (NRT) or bupropion.<br />Treatment discontinuation<br />The treatment discontinuation rate due to adverse reactions was 11.4% for varenicline compared with<br />9.7% for placebo. In this group, the discontinuation rates for the most common adverse reactions in<br />varenicline treated patients were as follows: nausea (2.7% vs. 0.6% for placebo), headache (0.6% vs.<br />1.0% for placebo), insomnia (1.3% vs. 1.2% for placebo), and abnormal dreams (0.2% vs. 0.2% for<br />placebo).<br />Analyses of Clinical Trials:<br />A meta-analysis of 5 randomised, double-blind, placebo controlled trials, including 1907 patients (1130<br />varenicline, 777 placebo), was conducted to assess suicidal ideation and behaviour as reported on the<br />Columbia-Suicide Severity Rating Scale (C-SSRS). This meta-analysis included one trial (N=127) in<br />patients with a history of schizophrenia or schizoaffective disorder and another trial (N=525) in patients<br />with a history of depression. The results showed no increase in the incidence of suicidal ideation and/or<br />behaviour in patients treated with varenicline compared to patients treated with placebo, as shown in the<br />table below. Of the 55 patients who reported suicidal ideation or behaviour, 48 (24 varenicline, 24<br />placebo) were from the two trials that enrolled patients with a history of schizophrenia/ schizoaffective<br />disorder, or of depression. Few patients reported these events in the other three trials (4 varenicline, 3<br />placebo).<br />Number of Patients and Risk Ratio for Suicidal Ideation and/or Behaviour Reported on C-SSRS<br />from a Meta- Analysis of 5 Clinical Trials Comparing Varenicline to Placebo:</p><table><tbody><tr><td>Varenicline<br />(N=1130)</td><td>Placebo<br />(N=777)</td></tr><tr><td>Patients with suicidal ideation and/or behaviour* [n (%)]**</td><td>28 (2.5)</td><td>27 (3.5)</td></tr><tr><td>Patient-years of exposure</td><td>325</td><td>217</td></tr><tr><td>Risk Ratio # (RR; 95% CI)</td><td>0.79 (0.46, 1.36)</td></tr><tr><td>* Of these, one patient in each treatment arm reported suicidal behaviour<br />** Patients with events up to 30 days after treatment; % are not weighted by study<br /># RR of incidence rates per 100 patient years</td></tr></tbody></table><p>A meta-analysis of 18 double-blind, randomised, placebo-controlled clinical trials was conducted to<br />assess the neuropsychiatric safety of varenicline. These trials included the 5 trials described above that<br />used the C-SSRS, and a total of 8521 patients (5072 varenicline, 3449 placebo), some of which had<br />psychiatric conditions. The results showed a similar incidence of combined neuropsychiatric adverse<br />events, other than sleep disorders, in patients treated with varenicline compared to patients treated with<br />placebo, with a risk ratio (RR) of 1.01 (95% CI: 0.89-1.15). Pooled data<br />from these 18 trials showed a similar incidence rate of individual categories of psychiatric events in<br />patients treated with varenicline compared to patients treated with placebo. The table below describes the<br />most frequently (&ge; 1%) reported categories of adverse events related to psychiatric safety other than sleep<br />disorders and disturbances.<br />Psychiatric Adverse Events Occurring in &ge; 1% of Patients from Pooled Data from 18 Clinical Trials:</p><table><tbody><tr><td>Varenicline<br />(N=5072)</td><td>Placebo<br />(N=3449)</td></tr><tr><td>Anxiety disorders and symptoms</td><td>253 (5.0)</td><td>206 (6.0)</td></tr><tr><td>Depressed mood disorders and disturbances</td><td>179 (3.5)</td><td>108 (3.1)</td></tr><tr><td>Mood disorders and disturbances NEC*</td><td>116 (2.3)</td><td>53 (1.5)</td></tr><tr><td>* NEC = Not Elsewhere Classified<br />Counts (percentages) corresponds to the number of patients reporting the event</td></tr></tbody></table><p>Observational Studies<br />Four observational studies, each including 10,000 to 30,000 users of varenicline in the adjusted analyses,<br />compared the risk of serious neuropsychiatric events, including neuropsychiatric hospitalizations and fatal<br />and non-fatal self-harm, in patients treated with varenicline versus patients prescribed NRT or bupropion.<br />All studies were retrospective cohort studies and included patients with and without a psychiatric history.<br />All studies used statistical methods to control for confounding factors, including preferential prescribing<br />of varenicline to healthier patients, although there is the possibility of residual confounding.<br />Two of the studies found no difference in risk of neuropsychiatric hospitalisations between varenicline<br />users and nicotine patch users (Hazard Ratio [HR] 1.14; 95% Confidence Interval [CI]: 0.56&ndash;2.34 in the<br />first study, and 0.76; 95% CI: 0.40-1.46 in the second study). The power to detect differences in these<br />two studies was limited. The third study reported no difference in risk of psychiatric adverse events<br />diagnosed during an emergency department visit or inpatient admission between varenicline users and<br />bupropion users (HR 0.85; 95% CI: 0.55-1.30). Based on post marketing reports, bupropion may be<br />associated with neuropsychiatric adverse events.<br />The fourth study showed no evidence of a higher risk of fatal and non-fatal self- harm (HR of 0.88; 95%<br />CI: 0.52-1.49) in patients prescribed varenicline compared to patients prescribed NRT. The occurrence of<br />detected suicide was rare during the three months after patients initiated any drug treatment (two cases in<br />31,260 varenicline users and six cases in 81,545 NRT users).<br />Pregnancy Cohort Study<br />A population-based cohort study compared infants exposed to CIMUQUIT in utero (N=335) with infants<br />born to mothers who smoked during pregnancy (N=78,412) and infants born to non-smoking mothers<br />(N=806,438). In this study, infants exposed to CIMUQUIT in utero as compared to infants born to<br />mothers who smoked during pregnancy had lower rates of congenital malformations (3.6% vs 4.3%),<br />stillbirth (0.3% vs 0.5%), preterm birth (7.5% vs 7.9%), small for gestational age (12.5% vs 17.1%), and<br />premature rupture of membrane (3.6% vs 5.4%).<br />Paediatric Population<br />The efficacy and safety of varenicline was evaluated in a randomised, double-blind, placebo-controlled<br />study of 312 patients aged 12 to 19 years, who smoked an average of at least 5 cigarettes per day during<br />the 30 days prior to recruitment, and had a score of at least 4 on the Fagerstrom Test for Nicotine<br />Dependence scale. Patients were stratified by age (12-16 years of age and 17-19 years of age) and by<br />body weight (&le;55 kg and &gt;55 kg). Following two-week titration, patients randomised to varenicline with<br />a body weight &gt;55 kg received 1 mg twice daily (high dose group) or 0.5 mg twice daily (low dose<br />group), while patients with a body weight &le;55 kg received 0.5 mg twice daily (high dose group) or 0.5<br />mg once daily (low dose group). Patients received treatment for 12 weeks, followed by a non-treatment<br />period of 40 weeks, along with age-appropriate counseling throughout the study.<br />The following table from the above paediatric study shows a comparison of continuous abstinence rates<br />(CAR) from weeks 9-12, confirmed by urine cotinine test, for the full analysis set overall study<br />population and the 12-17 year old population.</p><table><tbody><tr><td>CAR 9-12 (%)</td><td>Overall<br />n/N (%)</td><td>12-to-17-Year Olds<br />n/N (%)</td></tr><tr><td>High-Dose Varenicline</td><td>22/109 (20.2%)</td><td>15/80 (18.8%)</td></tr><tr><td>Low-Dose Varenicline</td><td>28/103 (27.2%)</td><td>25/78 (32.1%)</td></tr><tr><td>Placebo</td><td>18/100 (18.0%)</td><td>13/76 (17.1%)</td></tr><tr><td>Treatment Comparisons</td><td>Odds ratio in CAR 9-12 (95% CI) [p-value]</td></tr><tr><td>High-Dose Varenicline vs Placebo</td><td>1.18 (0.59, 2.37)<br />[0.6337]</td><td>1.13 (0.50, 2.56)<br />[0.7753]</td></tr><tr><td>Low-Dose Varenicline vs Placebo</td><td>1.73 (0.88, 3.39)<br />[0.1114]</td><td>2.28 (1.06, 4.89)<br />[0.0347]*</td></tr><tr><td>* This p value is not considered statistically significant. The prespecified statistical testing<br />procedures stopped testing after the high-dose varenicline vs Placebo treatment comparison in the<br />overall study did not achieve statistical significance.<br />CI=confidence interval; N=number of subjects randomised; n=the number of subjects who, at each<br />visit from weeks 9 to 12 (inclusive), reported no smoking and no use of other nicotine-containing<br />products since the last study visit/last contact (on the Nicotine Use Inventory) and at any of these<br />visits were confirmed to have quit based on urine cotinine tes</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Maximum plasma concentrations of varenicline occur typically within 3-4 hours after oral<br />administration. Following administration of multiple oral doses to healthy volunteers, steady-state<br />conditions were reached within 4 days.<br />Absorption is virtually complete after oral administration and systemic availability is high. Oral<br />bioavailability of varenicline is unaffected by food or time-of-day dosing.<br />Distribution<br />Varenicline distributes into tissues, including the brain. Apparent volume of distribution averaged 415<br />litres (%CV= 50) at steady-state. Plasma protein binding of varenicline is low (&le; 20%) and independent<br />of both age and renal function. In rodents, varenicline is transferred through the placenta and excreted<br />in milk.<br />Biotransformation<br />Varenicline undergoes minimal metabolism with 92% excreted unchanged in the urine and less than<br />10% excreted as metabolites. Minor metabolites in urine include varenicline N-carbamoylglucuronide<br />and hydroxyvarenicline. In circulation, varenicline comprises 91% of drug-related material. Minor<br />circulating metabolites include varenicline N- carbamoylglucuronide and N-glucosylvarenicline.<br />In vitro studies demonstrate that varenicline does not inhibit cytochrome P450 enzymes (IC50 &gt; 6,400<br />ng/ml). The P450 enzymes tested for inhibition were: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and<br />3A4/5. Also, in human hepatocytes in vitro, varenicline was shown to not induce the activity of<br />cytochrome P450 enzymes 1A2 and 3A4. Therefore, varenicline is unlikely to alter the<br />pharmacokinetics of compounds that are primarily metabolised by cytochrome P450 enzymes.<br />Elimination<br />The elimination half-life of varenicline is approximately 24 hours. Renal elimination of varenicline is<br />primarily through glomerular filtration along with active tubular secretion via the organic cationic<br />transporter, OCT2 (see section 4.5).<br />Linearity/Non-linearity<br />Varenicline exhibits linear kinetics when given as single (0.1 to 3 mg) or repeated 1 to 3 mg/day doses.<br />Pharmacokinetics in special patient populations<br />There are no clinically meaningful differences in varenicline pharmacokinetics due to age, race,<br />gender, smoking status, or use of concomitant medicinal products, as demonstrated in specific<br />pharmacokinetic studies and in population pharmacokinetic analyses.<br />Hepatic impairment<br />Due to the absence of significant hepatic metabolism, varenicline pharmacokinetics should be<br />unaffected in patients with hepatic impairment. (see section 4.2).<br />Renal impairment<br />Varenicline pharmacokinetics were unchanged in subjects with mild renal impairment (estimated<br />creatinine clearance &gt; 50 ml/min and &le; 80 ml/min). In patients with moderate renal impairment<br />(estimated creatinine clearance &ge; 30 ml/min and &le; 50 ml/min), varenicline exposure increased 1.5-fold<br />compared with subjects with normal renal function (estimated creatinine clearance &gt; 80 ml/min). In<br />subjects with severe renal impairment (estimated creatinine clearance &lt; 30 ml/min), varenicline<br />exposure was increased 2.1-fold. In subjects with end-stage-renal disease (ESRD), varenicline was<br />efficiently removed by haemodialysis (see section 4.2).<br />Elderly<br />The pharmacokinetics of varenicline in elderly patients with normal renal function (aged 65-75 years)<br />is similar to that of younger adult subjects (see section 4.2). For elderly patients with reduced renal<br />function please refer to section 4.2.<br />Paediatric population<br />Single and multiple-dose pharmacokinetics of varenicline have been investigated in paediatric patients<br />aged 12 to 17 years old (inclusive) and were approximately dose-proportional over the 0.5 mg to 2 mg<br />daily dose range studied.<br />Steady-state systemic exposure in adolescent patients of bodyweight &gt; 55 kg, as assessed by AUC (0-<br />24), was comparable to that noted for the same doses in the adult population. When 0.5 mg twice daily<br />was given, steady-state daily exposure of varenicline was, on average, higher (by approximately 40%)<br />in adolescent patients with bodyweight &le; 55 kg compared to that noted in the adult population.<br />CIMUQUIT is not recommended in paediatric patients because its efficacy in this population was not<br />demonstrated (see sections 4.2 and 5.1).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, fertility and embryo-foetal development. In male<br />rats dosed for 2 years with varenicline, there was a dose-related increase in the incidence of hibernoma<br />(tumour of the brown fat). In the offspring of pregnant rats treated with varenicline there were decreases<br />in fertility and increases in the auditory startle response (see section 4.6). These effects were observed<br />only at exposures considered sufficiently in excess of the maximum human exposure indicating little<br />relevance to clinical use. Nonclinical data indicate varenicline has reinforcing properties albeit with<br />lower potency than nicotine. In clinical studies in humans, varenicline showed low abuse potential.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet Core - Cimuquit 0.5 mg and 1 mg film-coated tablets<br />- Microcrystalline Cellulose<br />- Dicalcium Phosphate Anhydrous<br />- Croscarmellose Sodium (see section 2 &ldquo;Cimuquit contains sodium&rdquo;<br />- Colloidal Silica Anhydrous<br />- Magnesium Stearate<br />Tablet film coating - Cimuquit 0.5 mg film-coated tablets<br />- Opadry White (03A18480)<br />- Purified water<br />Tablet film coating - Cimuquit 1 mg film-coated tablets<br />- Opadry Blue (03A505009)<br />- Hypromellose (HPMC-E3)<br />- Purified water<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not Store above 30&deg;C<br />Keep out of the reach and sight of children<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cimuquit comes in two tablet strengths:<br />Cimuquit Tablets are provided in Blister packs (PVC blisters with aluminium foil backing). Blisters are<br />packed in a carton along with a patient information leaflet<br />Cimuquit film-coated tablets are provided in pack sizes of 25 tablets and 56 tablets<br />CIMUQUIT is available in the following pack presentations:<br />- A treatment initiation pack containing 2 blisters; 1 clear blister of 11 x CIMUQUIT 0.5 mg film coated<br />tablets and 1 clear blister of 14 x CIMUQUIT 1 mg film-coated tablets in a carton box packaging.<br />- A follow-on (maintenance) pack containing 4 clear blisters of 14 x CIMUQUIT 0.5 mg film-coated tablets<br />in in a carton box packaging.<br />- A follow-on (maintenance) pack containing 4 clear blisters of 14 x CIMUQUIT 1mg film coated tablets in in<br />a carton box packaging.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batterjee Pharmaceutical Factory (BATTERJEE PHARMA)
Plot E2, Phase 4, Industrial City, Jeddah, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>